MALDEN

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urina	<u>iry</u>		$\underline{\mathbf{M}}$	<u>lelanoma of</u>	<u>Skin</u>		
Male	40.79	43	105	Male	21.08	15	71
Female	17.12	14	82	Female	19.00	15	79
Total	57.91	57	98	Total	40.09	30	75
Brain and Cen	tral Nervous	System	$\underline{\mathbf{M}}$	<u>lultiple Mye</u>	<u>loma</u>		
Male	13.92	13	93	Male	7.30	4	NC*
Female	14.30	10	70	Female	7.55	13	172
Total	28.22	23	81	Total	14.86	17	114
Breast			No	on-Hodgkin	<u>'s Lymphoma</u>	<u>.</u>	
Male	2.16	2	NC*	Male	30.71	34	111
Female	265.00	281	106	Female	30.33	27	89
Total	267.15	283	106	Total	61.04	61	100
Cervix Uteri			<u>O</u> :	ral Cavity a	nd Pharynx		
				Male	26.92	42	156 ~+
Female	17.43	23	132	Female	13.49	14	104
				Total	40.42	56	139 #+
Colon / Rectur	<u>n</u>		<u>O</u>	<u>vary</u>			
Male	107.96	113	105				
Female	115.27	113	98	Female	32.05	35	109
Total	223.23	226	101				
Esophagus			<u>Pa</u>	ancreas			
Male	13.54	15	111	Male	14.79	11	74
Female	5.70	9	158	Female	17.97	16	89
Total	19.24	24	125	Total	32.76	27	82
Hodgkin's Dis	sease		<u>P</u> 1	<u>rostate</u>			
Male	6.84	6	88	Male	239.09	205	86 #-
Female	5.89	5	85				
Total	12.74	11	86				
Kidney and R	<u>enal Pelvis</u>		<u>St</u>	<u>omach</u>			
Male	23.23	34	146 #+	Male	17.99	10	56
Female	15.67	19	121	Female	12.70	14	110
Total	38.90	53	136 #+	Total	30.70	24	78
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	14.49	13	90	Male	10.60	17	160
Female	4.37	4	NC*				
Total	18.86	17	90				
Leukemia			<u>T</u>	<u>hyroid</u>			

1 of 87

Male	16.18	12	74	Male	4.12	6	146
Female	13.67	11	80	Female	12.22	5	41 #-
Total	29.85	23	77	Total	16.34	11	67
Liver and Intr	ahepatic Bile	<u>Ducts</u>	<u>U1</u>	t <mark>eri, Corpus</mark>	s and Uterus	, NOS	
Male	6.59	5	76				
Female	3.41	4	NC*	Female	49.01	38	78
Total	9.99	9	90				
Lung and Broi	<u>nchus</u>		<u>Al</u>	l Sites / Ty	pes		
Male	130.10	164	126 ~+	Male	805.93	835	104
Female	101.36	125	123 #+	Female	835.80	856	102
Total	231.46	289	125 ^+	Total	1641.73	1691	103

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} <= 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

MANCHESTER

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urina	<u>ry</u>		<u>M</u>	elanoma of S	<u>Skin</u>		
Male	4.65	4	NC*	Male	2.35	1	NC*
Female	1.76	0	NC*	Female	1.96	8	409 ~+
Total	6.41	4	NC*	Total	4.30	9	209
Brain and Cen	tral Nervous System Multiple Myeloma						
Male	1.52	0	NC*	Male	0.84	1	NC*
Female	1.49	1	NC*	Female	0.79	1	NC*
Total	3.02	1	NC*	Total	1.64	2	NC*
Breast			<u>N</u>	on-Hodgkin's	s Lymphoma	<u>1</u>	
Male	0.25	0	NC*	Male	3.31	3	NC*
Female	28.64	37	129	Female	3.11	2	NC*
Total	28.89	37	128	Total	6.43	5	78
Cervix Uteri			\mathbf{O}	ral Cavity an	nd Pharynx		

^{* =} SIR and statistical significance not calculated when Obs < 5

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

				Male	3.23	3	NC*
Female	1.72	1	NC*	Female	1.45	5	345 #+
				Total	4.68	8	171
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	12.36	10	81				
Female	11.73	10	85	Female	3.44	6	175
Total	24.09	20	83				
Esophagus			<u>Pa</u>	ancreas			
Male	1.64	4	NC*	Male	1.73	3	NC*
Female	0.58	1	NC*	Female	1.86	4	NC*
Total	2.22	5	225	Total	3.59	7	195
Hodgkin's Dis	<u>ease</u>		<u>Pı</u>	<u>rostate</u>			
Male	0.61	0	NC*	Male	27.94	42	150 #+
Female	0.53	1	NC*				
Total	1.13	1	NC*				
Kidney and Re	enal Pelvis		<u>St</u>	<u>omach</u>			
Male	2.76	2	NC*	Male	2.03	1	NC*
Female	1.68	0	NC*	Female	1.28	0	NC*
Total	4.43	2	NC*	Total	3.31	1	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	1.78	0	NC*	Male	0.80	2	NC*
Female	0.50	0	NC*				
Total	2.28	0	NC*				
<u>Leukemia</u>			<u>Tl</u>	<u>nyroid</u>			
Male	1.80	0	NC*	Male	0.41	0	NC*
Female	1.39	1	NC*	Female	1.18	1	NC*
Total	3.18	1	NC*	Total	1.58	1	NC*
Liver and Intra	ahepatic Bile	<u>Ducts</u>		<u>teri, Corpus</u>	and Uterus,	NOS	
Male	0.77	0	NC*				
Female	0.35	0	NC*	Female	5.45	7	129
Total	1.12	0	NC*				
Lung and Bron	<u>ichus</u>		<u>A</u>]	ll Sites / Ty	<u>pes</u>		
Male	15.59	7	45 #-	Male	92.69	86	93
Female	11.06	15	136	Female	88.34	106	120
Total	26.65	22	83	Total	181.02	192	106

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

MANSFIELD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		\mathbf{Exp}	<u>Obs</u>	<u>SIR</u>	
Bladder, Urina	<u>ry</u>		<u>M</u>	<u>lelanoma of</u>	<u>Skin</u>			
Male	8.36	12	144	Male	5.34	5	94	
Female	2.83	7	247	Female	4.44	3	NC*	
Total	11.19	19	170 #+	Total	9.77	8	82	
Brain and Cent	tral Nervous	<u>System</u>		<u>lultiple Mye</u>	<u>loma</u>			
Male	3.91	3	NC*	Male	1.55	0	NC*	
Female	3.35	4	NC*	Female	1.30	5	385 #+	
Total	7.26	7	96	Total	2.85	5	175	
Breast			No	<u>on-Hodgkin'</u>	s Lymphoma	<u>1</u>		
Male	0.48	0	NC*	Male	7.67	5	65	
Female	55.67	54	97	Female	5.73	5	87	
Total	56.15	54	96	Total	13.40	10	75	
Cervix Uteri		Oral Cavity and Pharynx						
				Male	6.86	6	87	
Female	4.53	1	NC*	Female	2.70	5	185	
				Total	9.56	11	115	
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>				
Male	22.22	16	72					
Female	18.36	20	109	Female	7.15	8	112	
Total	40.59	36	89					
Esophagus			<u>Pa</u>	ancreas_				
Male	3.14	3	NC*	Male	3.25	2	NC*	
Female	0.90	2	NC*	Female	2.97	6	202	
Total	4.04	5	124	Total	6.23	8	128	
Hodgkin's Disc	ease_		<u>P</u> 1	<u>rostate</u>				
Male	2.19	5	228	Male	47.56	46	97	
Female	1.72	1	NC*					
Total	3.91	6	153					
Kidney and Re	<u>nal Pelvis</u>		<u>St</u>	omach_				
Male	5.62	3	NC*	Male	3.77	2	NC*	
Female	3.11	4	NC*	Female	2.01	1	NC*	
Total	8.73	7	80	Total	5.77	3	NC*	
<u>Larynx</u>			<u>Te</u>	<u>estis</u>				

[~] indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	3.49	4	NC*	Male	3.52	7	199
Female	0.92	0	NC*				
Total	4.41	4	NC*				
Leukemia			<u>T</u>	<u>nyroid</u>			
Male	4.13	6	145	Male	1.23	1	NC*
Female	2.95	2	NC*	Female	3.34	1	NC*
Total	7.09	8	113	Total	4.58	2	NC*
Liver and Intr	ahepatic Bile I	<u>U</u> 1	teri, Corpus	and Uterus.	NOS		
Male	1.53	1	NC*				
Male Female	1.53 0.62	1 0	NC* NC*	Female	10.13	9	89
		_		Female	10.13	9	89
Female	0.62 2.16	0	NC* NC*	Female		9	89
Female Total	0.62 2.16	0	NC* NC*			9 165	89 92
Female Total Lung and Bron	0.62 2.16 nchus	0	NC* NC* <u>A</u> l	ll Sites / Ty	<u>pes</u>		
Female Total Lung and Brown Male	0.62 2.16 nchus 28.87	0 1 28	NC* NC* <u>Al</u> 97	l <mark>l Sites / Ty</mark> Male	<u>pes</u> 178.49	165	92

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

MARBLEHEAD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	SIR
Bladder, Urina	<u>ry</u>		$\underline{\mathbf{N}}$	<u>lelanoma of</u>			
Male	17.99	15	83	Male	9.07	15	165
Female	6.55	6	92	Female	7.42	22	297 ^+
Total	24.54	21	86	Total	16.49	37	224 ^+
Brain and Cent	ral Nervous S	<u>System</u>	$\underline{\mathbf{N}}$	<u>Iultiple Mye</u>	<u>loma</u>		
Male	5.82	9	155	Male	3.26	5	154
Female	5.61	6	107	Female	2.94	4	NC*
Total	11.43	15	131	Total	6.19	9	145
Breast			N	on-Hodgkin'	s Lymphoma	a	

5 of 87

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	0.96	1	NC*	Male	12.82	17	133
Female	106.75	140	131 ~+	Female	11.62	19	164
Total	107.71	141	131 ~+	Total	24.43	36	147 #+
Cervix Uteri			<u>O</u> 1	ral Cavity a	nd Pharynx	<u> </u>	
				Male	12.37	6	49
Female	6.64	7	105	Female	5.41	5	92
				Total	17.78	11	62
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	47.68	45	94				
Female	43.49	46	106	Female	12.87	13	101
Total	91.17	91	100				
Esophagus			<u>Pa</u>	ncreas			
Male	6.27	6	96	Male	6.62	7	106
Female	2.16	3	NC*	Female	6.87	6	87
Total	8.43	9	107	Total	13.49	13	96
Hodgkin's Dis	sease_		<u>Pr</u>	<u>costate</u>			
Male	2.37	3	NC*	Male	106.08	127	120
Female	2.07	2	NC*				
Total	4.44	5	113				
Kidney and Ro	enal Pelvis		St	<u>omach</u>			
Male	10.52	10	95	Male	7.90	7	89
Female	6.21	4	NC*	Female	4.76	3	NC*
Total	16.72	14	84	Total	12.66	10	79
<u>Larynx</u>			<u>Te</u>	<u>estis</u>			
Male	6.78	3	NC*	Male	3.20	4	NC*
Female	1.85	1	NC*				
Total	8.63	4	NC*				
Leukemia			<u>Tł</u>	<u> </u>			
Male	6.87	17	247 ~+	Male	1.58	4	NC*
Female	5.19	14	269 ~+	Female	4.56	3	NC*
Total	12.07	31	257 ^+	Total	6.15	7	114
Liver and Intr	<u>ahepatic Bile</u>	<u>Ducts</u>	<u>U1</u>	t <mark>eri, Corpus</mark>	and Uteru	s, NOS	
Male	2.95	1	NC*				
Female	1.31	3	NC*	Female	20.17	21	104
Total	4.25	4	NC*				
Lung and Bron	<u>nchus</u>		<u>A</u> l	ll Sites / Ty	pes		
Male	59.24	36	61 ~-	Male	354.71	356	100
Female	40.71	47	115	Female	328.99	398	121 ^+
Total	99.95	83	83	Total	683.70	754	110 ~+

 $\mathbf{Exp} = \text{expected case count}$, based on the Massachusetts average age-specific incidence rates for this cancer $\mathbf{Obs} = \text{observed case count}$

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} <= 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} <= 0.001$ level, as well as at the $\mathbf{p} <= 0.05$ and $\mathbf{p} <= 0.01$ levels

MARION

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urinaı	<u>ry</u>		<u>M</u>	<u>lelanoma of</u>	<u>Skin</u>				
Male	4.27	6	141	Male	2.09	4	NC*		
Female	1.25	1	NC*	Female	1.52	0	NC*		
Total	5.52	7	127	Total	3.61	4	NC*		
Brain and Cent	ral Nervous	<u>System</u>	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>				
Male	1.39	1	NC*	Male	0.77	0	NC*		
Female	1.19	2	NC*	Female	0.57	0	NC*		
Total	2.58	3	NC*	Total	1.34	0	NC*		
Breast			No	on-Hodgkin'	s Lymphoma	<u>1</u>			
Male	0.22	0	NC*	Male	3.02	6	199		
Female	21.58	18	83	Female	2.30	3	NC*		
Total	21.80	18	83	Total	5.32	9	169		
<u>Cervix Uteri</u>		Oral Cavity and Pharynx							
				Male	2.78	4	NC*		
Female	1.40	2	NC*	Female	1.09	1	NC*		
				Total	3.87	5	129		
Colon / Rectum	<u>_</u>		<u>O</u>	<u>vary</u>					
Male	11.31	8	71						
Female	8.21	10	122	Female	2.64	2	NC*		
Total	19.51	18	92						
Esophagus			<u>Pa</u>	ancreas					
Male	1.43	3	NC*	Male	1.55	2	NC*		
Female	0.41	0	NC*	Female	1.33	1	NC*		
Total	1.85	3	NC*	Total	2.88	3	NC*		
Hodgkin's Dise	<u>ease</u>		<u>P1</u>	<u>rostate</u>					
Male	0.59	1	NC*	Male	25.37	30	118		
Female	0.47	1	NC*						
Total	1.06	2	NC*						

Kidney and R	enal Pelvis		St	<u>omach</u>				
Male	2.43	6	247	Male	1.87	1	NC*	
Female	1.27	2	NC*	Female	0.88	0	NC*	
Total	3.71	8	216	Total	2.74	1	NC*	
<u>Larynx</u>			<u>T</u>	<u>estis</u>				
Male	1.54	1	NC*	Male	0.79	1	NC*	
Female	0.38	0	NC*					
Total	1.92	1	NC*					
Leukemia			<u>Tl</u>	<u>iyroid</u>				
Male	1.67	1	NC*	Male	0.37	0	NC*	
Female	1.07	4	NC*	Female	0.98	1	NC*	
Total	2.74	5	183	Total	1.35	1	NC*	
Liver and Inti	rahepatic Bile	<u>Ducts</u>	<u>U</u> 1	t <mark>eri, Corpus</mark>	, Corpus and Uterus, NOS			
Male	0.69	0	NC*					
Female	0.26	0	NC*	Female	4.13	3	NC*	
Total	0.95	0	NC*					
Lung and Bro	<u>nchus</u>		<u>A</u>]	ll Sites / Ty	<u>pes</u>			
Male	13.80	7	51	Male	83.74	83	99	
Female	8.41	4	NC*	Female	66.01	64	97	
Total	22.21	11	50 #-	Total	149.75	147	98	

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

MARLBOROUGH

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urina	<u>ry</u>	Melanoma of Skin						
Male	20.06	25	125	Male	11.56	14	121	
Female	8.19	4	NC*	Female	9.94	13	131	
Total	28.25	29	103	Total	21.50	27	126	

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Brain and Cent	tral Nervous	System	Multiple Myeloma				
Male	7.96	8	101	Male	3.66	5	137
Female	7.42	12	162	Female	3.62	3	NC*
Total	15.38	20	130	Total	7.28	8	110
Breast			<u>N</u>	on-Hodgkin	's Lymphon	<u>1a</u>	
Male	1.10	2	NC*	Male	16.64	18	108
Female	133.84	133	99	Female	14.90	8	54
Total	134.95	135	100	Total	31.54	26	82
Cervix Uteri			<u>O</u>	ral Cavity a	<u>nd Pharynx</u>	•	
				Male	14.94	19	127
Female	9.41	15	159	Female	6.75	7	104
				Total	21.68	26	120
Colon / Rectum	<u>l</u>		<u>O</u>	<u>vary</u>			
Male	53.33	46	86				
Female	54.67	63	115	Female	16.46	17	103
Total	107.99	109	101				
Esophagus			<u>Pa</u>	ancreas			
Male	7.14	4	NC*	Male	7.60	6	79
Female	2.69	0	NC*	Female	8.52	9	106
Total	9.84	4	NC*	Total	16.13	15	93
Hodgkin's Dis	<u>ease</u>			<u>rostate</u>			
Male	4.16	3	NC*	Male	117.63	117	99
Female	3.28	2	NC*				
Total	7.45	5	67				
Kidney and Re	nal Pelvis			<u>omach</u>			
Male	12.51	14	112	Male	8.92	11	123
Female	7.72	6	78	Female	6.07	7	115
Total	20.23	20	99	Total	14.99	18	120
<u>Larynx</u>			_	<u>estis</u>			
Male	7.84	8	102	Male	6.66	5	75
Female	2.19	1	NC*				
Total	10.04	9	90				
<u>Leukemia</u>				<u>hyroid</u>			
Male	8.72	18	206 ~+	Male	2.47	4	NC*
Female	6.98	11	157	Female	6.71	3	NC*
Total	15.71	29	185 ~+	Total	9.18	7	76
Liver and Intra	_			<u>teri, Corpus</u>	and Uterus	s, NOS	
Male	3.47	6	173		24.70	4=	
Female	1.65	4	NC*	Female	24.50	17	69
Total	5.13	10	195	U C!4 / F			
Lung and Bron		00		ll Sites / Ty		4.40	100
Male	67.50	88	130 #+	Male	414.27	448	108
Female	49.11	52	106	Female	415.25	416	100
Total	116.61	140	120 #+	Total	829.52	864	104

SIR = standardized incidence ratio [(Obs / Exp) X 100]

MARSHFIELD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		\mathbf{Exp}	<u>Obs</u>	<u>SIR</u>
Bladder, Urinar	<u>y</u>		<u>M</u>	elanoma of	<u>Skin</u>		
Male	12.92	15	116	Male	7.65	13	170
Female	4.33	4	NC*	Female	6.20	9	145
Total	17.25	19	110	Total	13.86	22	159
Brain and Cent	ral Nervous S	<u>System</u>	Multiple Myeloma				
Male	5.39	6	111	Male	2.39	1	NC*
Female	4.69	4	NC*	Female	2.00	2	NC*
Total	10.08	10	99	Total	4.39	3	NC*
Breast			No	<u>on-Hodgkin'</u>	s Lymphoma	<u>a</u> _	
Male	0.73	0	NC*	Male	10.84	8	74
Female	83.04	89	107	Female	8.40	12	143
Total	83.76	89	106	Total	19.24	20	104
<u>Cervix Uteri</u>			<u>O</u> :	<u>ral Cavity ar</u>	<u>nd Pharynx</u>		
				Male	10.27	14	136
Female	6.05	6	99	Female	4.08	9	221 #+
				Total	14.35	23	160 #+
Colon / Rectum	•		<u>O</u>	<u>vary</u>			
Male	34.43	41	119				
Female	27.92	30	107	Female	10.41	15	144
Total	62.35	71	114				
Esophagus			<u>Pa</u>	ancreas			
Male	4.85	7	144	Male	5.02	4	NC*
Female	1.39	1	NC*	Female	4.56	5	110
Total	6.25	8	128	Total	9.58	9	94

^{* =} **SIR** and statistical significance not calculated when **Obs** < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Hodgkin's Disc	Hodgkin's Disease P				<u>rostate</u>			
Male	2.67	9	338 ~+	Male	75.93	102	134 ~+	
Female	2.09	4	NC*					
Total	4.75	13	274 ~+					
Kidney and Re	nal Pelvis		<u>St</u>	Stomach				
Male	8.49	7	82	Male	5.75	4	NC*	
Female	4.67	7	150	Female	3.02	2	NC*	
Total	13.16	14	106	Total	8.76	6	68	
<u>Larynx</u>			<u>T</u>	<u>estis</u>				
Male	5.40	3	NC*	Male	4.03	9	224 #+	
Female	1.45	2	NC*					
Total	6.85	5	73					
<u>Leukemia</u>			<u>Tl</u>	<u> </u>				
Male	5.86	6	102	Male	1.61	4	NC*	
Female	4.08	3	NC*	Female	4.32	7	162	
Total	9.93	9	91	Total	5.92	11	186	
Liver and Intra	<u>ahepatic Bile</u>	<u>Ducts</u>	<u>U</u> 1	t <mark>eri, Corpus</mark>	and Uterus.	NOS		
Male	2.33	2	NC*					
Female	0.92	1	NC*	Female	15.58	19	122	
Total	3.25	3	NC*					
Lung and Bron	chus		<u>A</u>]	ll Sites / Ty	<u>pes</u>			
Male	45.17	53	117	Male	271.57	329	121 ^+	
Female	30.26	40	132	Female	246.33	293	119 ~+	
Total	75.43	93	123	Total	517.90	622	120 ^+	

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

MASHPEE

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

<u>Exp</u> <u>Obs</u> <u>SIR</u> <u>Exp</u> <u>Obs</u> <u>SIR</u>

11 of 87

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Bladder, Urinar	<u>v</u>		<u>M</u>	lelanoma of	<u>Skin</u>		
Male	7.14	8	112	Male	3.58	1	NC*
Female	2.54	1	NC*	Female	2.93	3	NC*
Total	9.67	9	93	Total	6.51	4	NC*
Brain and Cent	ral Nervous S	<u>System</u>	$\underline{\mathbf{M}}$	<u>lultiple Mye</u>	<u>loma</u>		
Male	2.39	4	NC*	Male	1.28	1	NC*
Female	2.24	1	NC*	Female	1.12	1	NC*
Total	4.63	5	108	Total	2.40	2	NC*
Breast			<u>N</u>	on-Hodgkin'	s Lymphoma	<u>1</u>	
Male	0.37	0	NC*	Male	5.22	6	115
Female	40.35	40	99	Female	4.54	4	NC*
Total	40.72	40	98	Total	9.76	10	102
Cervix Uteri			<u>O</u>	ral Cavity a	nd Pharynx		
				Male	4.64	4	NC*
Female	2.71	5	184	Female	2.06	1	NC*
				Total	6.70	5	75
Colon / Rectum	_		<u>O</u>	<u>vary</u>			
Male	18.89	28	148				
Female	16.92	17	100	Female	4.92	6	122
Total	35.81	45	126				
Esophagus			<u>Pa</u>	ancreas			
Male	2.37	0	NC*	Male	2.58	3	NC*
Female	0.84	0	NC*	Female	2.65	7	264 #+
Total	3.21	0	NC*	Total	5.23	10	191
Hodgkin's Dise	ease_		<u>P</u> 1	<u>rostate</u>			
Male	1.11	1	NC*	Male	42.18	76	180 ^+
Female	0.94	0	NC*				
Total	2.05	1	NC*				
Kidney and Re	nal Pelvis		St	<u>omach</u>			
Male	4.04	3	NC*	Male	3.14	3	NC*
Female	2.38	4	NC*	Female	1.86	0	NC*
Total	6.42	7	109	Total	5.00	3	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	2.53	2	NC*	Male	1.62	6	371 #+
Female	0.68	0	NC*				
Total	3.21	2	NC*				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	2.84	3	NC*	Male	0.67	1	NC*
Female	2.12	0	NC*	Female	1.92	3	NC*
Total	4.96	3	NC*	Total	2.59	4	NC*
Liver and Intra	hepatic Bile	Ducts	<u>U</u> 1	teri, Corpus	and Uterus,	NOS_	
Male	1.15	3	NC*				
Female	0.51	0	NC*	Female	7.48	8	107
Total	1.66	3	NC*				

Lung and Bronchus			All Sites / Types					
Male	22.79	24	105	Male	140.45	190	135 ^+	
Female	15.23	18	118	Female	126.31	127	101	
Total	38.03	42	110	Total	266.75	317	119 ~+	

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

MATTAPOISETT

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		\mathbf{Exp}	<u>Obs</u>	<u>SIR</u>	
Bladder, Urinary	<u>-</u>		<u>M</u>	elanoma of S	<u>Skin</u>			
Male	5.15	5	97	Male	2.63	3	NC*	
Female	1.90	2	NC*	Female	2.11	2	NC*	
Total	7.05	7	99	Total	4.75	5	105	
Brain and Centr	al Nervous	<u>System</u>	Multiple Myeloma					
Male	1.72	1	NC*	Male	0.93	0	NC*	
Female	1.63	0	NC*	Female	0.85	1	NC*	
Total	3.35	1	NC*	Total	1.79	1	NC*	
Breast			No	on-Hodgkin's	s Lymphoma	<u>1</u>		
Male	0.28	0	NC*	Male	3.74	1	NC*	
Female	30.65	33	108	Female	3.36	1	NC*	
Total	30.92	33	107	Total	7.10	2	NC*	
Cervix Uteri			<u>O</u> 1	ral Cavity an	<u>d Pharynx</u>			
				Male	3.57	2	NC*	
Female	1.88	1	NC*	Female	1.56	3	NC*	
				Total	5.12	5	98	
Colon / Rectum		<u>Ovary</u>						
Male	13.66	9	66					
Female	12.62	13	103	Female	3.69	2	NC*	
Total	26.28	22	84					

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Esophagus			<u>Pa</u>	ancreas				
Male	1.80	1	NC*	Male	1.90	6	316 #+	
Female	0.63	1	NC*	Female	2.00	2	NC*	
Total	2.43	2	NC*	Total	3.90	8	205	
Hodgkin's Dis	<u>ease</u>		Prostate					
Male	0.73	0	NC*	Male	30.39	35	115	
Female	0.59	1	NC*					
Total	1.32	1	NC*					
Kidney and Re	enal Pelvis		<u>St</u>	<u>omach</u>				
Male	3.04	1	NC*	Male	2.26	1	NC*	
Female	1.81	0	NC*	Female	1.37	3	NC*	
Total	4.84	1	NC*	Total	3.64	4	NC*	
<u>Larynx</u>			<u>T</u>	<u>estis</u>				
Male	1.95	2	NC*	Male	1.00	1	NC*	
Female	0.53	1	NC*					
Total	2.48	3	NC*					
Leukemia			<u>Tl</u>	<u>hyroid</u>				
Male	2.02	1	NC*	Male	0.47	0	NC*	
Female	1.51	4	NC*	Female	1.29	1	NC*	
Total	3.52	5	142	Total	1.76	1	NC*	
Liver and Intra	ahepatic Bile	<u>Ducts</u>	<u>U</u> 1	teri, Corpus	and Uterus,	NOS		
Male	0.85	1	NC*					
Female	0.38	1	NC*	Female	5.82	7	120	
Total	1.23	2	NC*					
Lung and Bron	<u>chus</u>		<u>A</u>]	ll Sites / Ty	<u>pes</u>			
Male	17.01	12	71	Male	102.18	86	84	
Female	11.90	14	118	Female	94.98	104	109	
Total	28.91	26	90	Total	197.17	190	96	

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

MAYNARD

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\bar{\bf p}$ <= 0.001 level, as well as at the $\bar{\bf p}$ <= 0.05 and $\bar{\bf p}$ <= 0.01 levels

Cancer Incidence by Sex, 1990 - 1995 Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
<u>Bladder, Urinaı</u>	<u>ry</u>		$\underline{\mathbf{M}}$	<u>lelanoma of</u>	<u>Skin</u>		
Male	7.04	12	170	Male	3.87	2	NC*
Female	2.76	4	NC*	Female	3.28	2	NC*
Total	9.80	16	163	Total	7.16	4	NC*
Brain and Cent	<u>ral Nervous S</u>	<u>System</u>	$\underline{\mathbf{M}}$	<u>lultiple Mye</u>	<u>loma</u>		
Male	2.62	4	NC*	Male	1.28	0	NC*
Female	2.48	1	NC*	Female	1.23	2	NC*
Total	5.11	5	98	Total	2.51	2	NC*
Breast			No	<u>on-Hodgkin'</u>	s Lymphoma	<u>1</u>	
Male	0.38	0	NC*	Male	5.59	4	NC*
Female	45.30	55	121	Female	5.01	11	219 #+
Total	45.68	55	120	Total	10.60	15	142
Cervix Uteri			Oral Cavity and Pharynx				
				Male	4.99	4	NC*
Female	3.07	4	NC*	Female	2.27	1	NC*
				Total	7.27	5	69
Colon / Rectum	_		<u>O</u>	<u>vary</u>			
Male	18.66	16	86				
Female	18.40	14	76	Female	5.54	7	126
Total	37.06	30	81				
Esophagus			<u>Pa</u>	ancreas			
Male	2.44	3	NC*	Male	2.60	1	NC*
Female	0.91	1	NC*	Female	2.91	1	NC*
Total	3.35	4	NC*	Total	5.51	2	NC*
Hodgkin's Disc	ease_		<u>P</u> 1	<u>rostate</u>			
Male	1.32	2	NC*	Male	40.66	45	111
Female	1.05	0	NC*				
Total	2.37	2	NC*				
Kidney and Re	nal Pelvis		St	tomach_			
Male	4.22	4	NC*	Male	3.13	8	256 #+
Female	2.65	3	NC*	Female	2.01	1	NC*
Total	6.87	7	102	Total	5.14	9	175
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	2.64	1	NC*	Male	2.06	2	NC*
Female	0.76	0	NC*				
Total	3.40	1	NC*				
Leukemia			<u>T</u>	<u>hvroid</u>			
Male	2.95	5	169	Male	0.79	0	NC*
Female	2.31	1	NC*	Female	2.17	3	NC*

15 of 87

Total	5.26	6	114	Total	2.96	3	NC*			
Liver and Intrahepatic Bile Ducts			<u>U</u> 1	<u>Uteri, Corpus and Uterus, NOS</u>						
Male	1.18	0	NC*							
Female	0.56	0	NC*	Female	8.41	12	143			
Total	1.74	0	NC*							
Lung and Bron	<u>chus</u>		<u>A</u>]	All Sites / Types						
Male	23.01	22	96	Male	141.80	147	104			
Female	17.17	14	82	Female	140.47	147	105			
Total	40.18	36	90	Total	282.27	294	104			

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

MEDFIELD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urina	<u>ry</u>	Melanoma of Skin							
Male	6.38	7	110	Male	3.83	4	NC*		
Female	2.22	1	NC*	Female	3.08	8	260 #+		
Total	8.61	8	93	Total	6.91	12	174		
Brain and Cent	ral Nervous S	<u>System</u>	<u>M</u>	ultiple Mye	<u>loma</u>				
Male	2.71	2	NC*	Male	1.19	4	NC*		
Female	2.35	1	NC*	Female	1.03	2	NC*		
Total	5.06	3	NC*	Total	2.21	6	271		
Breast			No	on-Hodgkin'	s Lymphoma	<u>a</u>			
Male	0.36	1	NC*	Male	5.36	8	149		
Female	42.09	41	97	Female	4.24	15	354 ^+		
Total	42.45	42	99	Total	9.60	23	239 ^+		
Cervix Uteri		Oral Cavity and Pharynx							
				Male	5.26	5	95		
Female	2.94	3	NC*	Female	2.08	3	NC*		

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

				Total	7.34	8	109
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	17.05	14	82				
Female	14.31	7	49	Female	5.24	4	NC*
Total	31.36	21	67				
Esophagus			<u>Pa</u>	ancreas			
Male	2.47	0	NC*	Male	2.53	2	NC*
Female	0.72	3	NC*	Female	2.33	1	NC*
Total	3.19	3	NC*	Total	4.86	3	NC*
Hodgkin's Disc	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Male	1.29	3	NC*	Male	38.19	33	86
Female	0.99	1	NC*				
Total	2.28	4	NC*				
Kidney and Re	enal Pelvis		St	<u>omach</u>			
Male	4.31	5	116	Male	2.83	4	NC*
Female	2.37	3	NC*	Female	1.55	1	NC*
Total	6.68	8	120	Total	4.38	5	114
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	2.78	3	NC*	Male	1.89	4	NC*
Female	0.74	2	NC*				
Total	3.53	5	142				
<u>Leukemia</u>			<u>Tl</u>	<u>hyroid</u>			
Male	2.92	1	NC*	Male	0.79	1	NC*
Female	2.05	3	NC*	Female	2.08	1	NC*
Total	4.97	4	NC*	Total	2.87	2	NC*
Liver and Intra	<u>ahepatic Bile l</u>	<u>Ducts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	NOS	
Male	1.18	0	NC*				
Female	0.47	0	NC*	Female	7.96	9	113
Total	1.65	0	NC*				
Lung and Bron	<u>ichus</u>		$\underline{\mathbf{A}}$	ll Sites / Ty			
Male	22.96	10	44 ~-	Male	136.11	121	89
Female	15.40	15	97	Female	124.83	134	107
Total	38.37	25	65 #-	Total	260.94	255	98

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

MEDFORD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urina	<u>ry</u>		$\underline{\mathbf{M}}$	<u>lelanoma of</u>	<u>Skin</u>		
Male	46.50	50	108	Male	23.44	16	68
Female	19.89	21	106	Female	21.36	22	103
Total	66.39	71	107	Total	44.80	38	85
Brain and Cen	<u>tral Nervous</u>	System	$\underline{\mathbf{M}}$	<u>lultiple Mye</u>	<u>loma</u>		
Male	15.34	16	104	Male	8.34	6	72
Female	16.26	10	62	Female	8.81	13	148
Total	31.60	26	82	Total	17.15	19	111
Breast			<u>N</u>	on-Hodgkin	<u>s Lymphoma</u>	_	
Male	2.45	6	245	Male	34.06	27	79
Female	304.38	306	101	Female	34.94	53	152 ~+
Total	306.83	312	102	Total	69.00	80	116
<u>Cervix Uteri</u>		Oral Cavity and Pharynx					
				Male	30.41	31	102
Female	19.22	12	62	Female	15.56	19	122
				Total	45.97	50	109
Colon / Rectum	_			<u>vary</u>			
Male	123.29	156	127 ~+				
Female	134.05	153	114	Female	36.55	36	99
Total	257.34	309	120 ~+				
Esophagus				<u>ancreas</u>			
Male	15.49	20	129	Male	16.89	18	107
Female	6.65	3	NC*	Female	20.99	17	81
Total	22.13	23	104	Total	37.88	35	92
Hodgkin's Dis				<u>rostate</u>			
Male	7.13	13	182	Male	276.64	246	89
Female	6.36	4	NC*				
Total	13.48	17	126				
Kidney and Re			· · · · · · · · · · · · · · · · · · ·	<u>omach</u>			
Male	26.45	29	110	Male	20.40	25	123
Female	18.20	17	93	Female	14.69	17	116
Total	44.64	46	103	Total	35.09	42	120
<u>Larynx</u>				<u>estis</u>			
Male	16.59	24	145	Male	10.65	6	56

18 of 87

Female	5.09	3	NC*				
Total	21.68	27	125				
Leukemia			<u>T</u>	<u>nyroid</u>			
Male	18.07	25	138	Male	4.41	3	NC*
Female	15.55	11	71	Female	13.34	18	135
Total	33.62	36	107	Total	17.74	21	118
Liver and Int	rahepatic Bile	Ducts	<u>Uteri, Corpus and Uterus, NOS</u>				
Male	7.50	5	67				
Female	3.96	4	NC*	Female	56.85	67	118
Total	11.45	9	79				
Lung and Bro	<u>nchus</u>		<u>A</u> l	ll Sites / Ty	pes		
Male	149.78	160	107	Male	918.15	943	103
Female	118.81	148	125 #+	Female	963.18	1034	107 #+
Total	268.60	308	115 #+	Total	1881.33	1977	105 #+

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

MEDWAY

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR	
Bladder, Urinar	<u>v</u>	Melanoma of Skin						
Male	5.87	14	238 ~+	Male	3.47	5	144	
Female	2.46	5	203	Female	3.07	2	NC*	
Total	8.34	19	228 ~+	Total	6.54	7	107	
Brain and Central Nervous System			<u>M</u>	ultiple Myel	<u>loma</u>			
Male	2.46	2	NC*	Male	1.09	2	NC*	
Female	2.32	1	NC*	Female	1.09	0	NC*	
Total	4.78	3	NC*	Total	2.18	2	NC*	
Breast			<u>No</u>	on-Hodgkin's	s Lymphoma	<u>1</u>		
Male	0.33	0	NC*	Male	4.93	6	122	

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]thicksim$ indicates statistical significance at the p <= 0.01 level, as well as at the p <= 0.05 level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	41.28	34	82	Female	4.51	3	NC*
Total	41.61	34	82	Total	9.44	9	95
Cervix Uteri			<u>O</u> :	ral Cavity a	nd Pharynx		
				Male	4.64	5	108
Female	2.90	2	NC*	Female	2.08	2	NC*
				Total	6.71	7	104
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>			
Male	15.66	21	134				
Female	16.36	16	98	Female	5.11	4	NC*
Total	32.01	37	116				
Esophagus			<u>Pa</u>	ancreas			
Male	2.19	2	NC*	Male	2.28	2	NC*
Female	0.80	0	NC*	Female	2.55	2	NC*
Total	3.00	2	NC*	Total	4.83	4	NC*
Hodgkin's Disc	<u>ease</u>		<u>Pr</u>	<u>rostate</u>			
Male	1.23	1	NC*	Male	34.66	38	110
Female	1.02	2	NC*				
Total	2.25	3	NC*				
Kidney and Re	-			<u>omach</u>			
Male	3.85	2	NC*	Male	2.61	5	192
Female	2.36	1	NC*	Female	1.83	1	NC*
Total	6.21	3	NC*	Total	4.44	6	135
<u>Larynx</u>				<u>estis</u>			
Male	2.44	4	NC*	Male	1.85	2	NC*
Female	0.68	0	NC*				
Total	3.12	4	NC*				
<u>Leukemia</u>				<u>nyroid</u>			
Male	2.68	3	NC*	Male	0.73	0	NC*
Female	2.19	2	NC*	Female	2.08	1	NC*
Total	4.87	5	103	Total	2.81	1	NC*
Liver and Intra	_			<u>teri, Corpus</u>	and Uterus	<u>NOS</u>	
Male	1.06	0	NC*				
Female	0.50	0	NC*	Female	7.56	10	132
Total	1.56	0	NC*				
Lung and Bron				ll Sites / Ty			
Male	20.50	27	132	Male	123.56	153	124 #+
Female	14.82	10	67	Female	126.92	112	88
Total	35.32	37	105	Total	250.48	265	106

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

MELROSE

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urina	ry		<u>M</u>	<u>lelanoma of</u>	Skin			
Male	23.03	20	87	Male	11.49	14	122	
Female	10.12	12	119	Female	10.38	12	116	
Total	33.14	32	97	Total	21.87	26	119	
Brain and Cen	rain and Central Nervous System Multiple Mye			<u>eloma</u>				
Male	7.42	7	94	Male	4.13	5	121	
Female	7.89	10	127	Female	4.43	8	180	
Total	15.31	17	111	Total	8.57	13	152	
Breast			<u>N</u>	on-Hodgkin	's Lymphom	<u>a</u>		
Male	1.21	2	NC*	Male	16.51	11	67	
Female	150.01	147	98	Female	17.41	15	86	
Total	151.22	149	99	Total	33.92	26	77	
Cervix Uteri		Oral Cavity and Pharynx						
				Male	15.14	6	40 #-	
Female	9.08	9	99	Female	7.72	11	143	
				Total	22.86	17	74	
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>				
Male	60.86	52	85					
Female	68.52	81	118	Female	17.87	24	134	
Total	129.38	133	103					
Esophagus			<u>Pa</u>	ancreas				
Male	7.73	2	NC*	Male	8.31	8	96	
Female	3.38	2	NC*	Female	10.58	10	94	
Total	11.11	4	NC*	Total	18.89	18	95	
Hodgkin's Dis	<u>ease</u>		<u>P</u> 1	<u>rostate</u>				
Male	3.26	2	NC*	Male	134.17	110	82 #-	
Female	2.92	5	171					
Total	6.18	7	113					
Kidney and Ro	enal Pelvis		<u>St</u>	<u>omach</u>				
Male	13.02	9	69	Male	10.13	12	118	

Female	8.94	11	123	Female	7.60	5	66
Total	21.96	20	91	Total	17.73	17	96
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	8.25	9	109	Male	4.67	6	128
Female	2.48	3	NC*				
Total	10.74	12	112				
Leukemia			<u>Tl</u>	<u>nyroid</u>			
Male	8.82	5	57	Male	2.07	7	338 #+
Female	7.75	11	142	Female	6.25	4	NC*
Total	16.58	16	97	Total	8.33	11	132
Liver and Intr	<u>ahepatic Bile</u>	Ducts	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus	, NOS	
Male	3.68	5	136				
Female	1.97	1	NC*	Female	27.89	23	82
Total	5.66	6	106				
Lung and Bron	<u>nchus</u>		$\underline{\mathbf{A}}$	ll Sites / Ty	pes		
Male	73.47	63	86	Male	448.79	382	85 ~-
Female	57.80	55	95	Female	477.21	493	103
Total	131.27	118	90	Total	925.99	875	94

SIR = standardized incidence ratio [(Obs / Exp) X 100]

MENDON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		\mathbf{Exp}	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary	<u>/</u>		<u>M</u>	elanoma of S	<u>Skin</u>		
Male	2.70	5	185	Male	1.57	1	NC*
Female	0.86	3	NC*	Female	1.19	0	NC*
Total	3.56	8	225	Total	2.76	1	NC*
Brain and Centr	al Nervous S	<u>System</u>					
Male	1.09	3	NC*	Male	0.50	0	NC*

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	0.91	0	NC*	Female	0.40	0	NC*
Total	2.00	3	NC*	Total	0.89	0	NC*
Breast					's Lymphom	a	
Male	0.15	1	NC*	Male	2.23	_ 2	NC*
Female	16.03	16	100	Female	1.65	0	NC*
Total	16.18	17	105	Total	3.88	2	NC*
Cervix Uteri			<u>O</u> 1	ral Cavity a	nd Pharynx		
				Male	2.07	2	NC*
Female	1.16	0	NC*	Female	0.79	0	NC*
				Total	2.87	2	NC*
Colon / Rectun	<u>n</u>		<u>O</u>	<u>vary</u>			
Male	7.16	3	NC*				
Female	5.59	9	161	Female	2.01	2	NC*
Total	12.75	12	94				
Esophagus			<u>Pa</u>	<u>ancreas</u>			
Male	0.99	0	NC*	Male	1.03	0	NC*
Female	0.28	0	NC*	Female	0.91	0	NC*
Total	1.26	0	NC*	Total	1.93	0	NC*
Hodgkin's Dis	sease_		<u>P</u> 1	<u>rostate</u>			
Male	0.54	0	NC*	Male	15.45	12	78
Female	0.40	1	NC*				
Total	0.95	1	NC*				
Kidney and Re	<u>enal Pelvis</u>		<u>St</u>	<u>omach</u>			
Male	1.71	3	NC*	Male	1.21	1	NC*
Female	0.91	0	NC*	Female	0.61	1	NC*
Total	2.62	3	NC*	Total	1.81	2	NC*
<u>Larynx</u>				<u>estis</u>			
Male	1.09	1	NC*	Male	0.83	2	NC*
Female	0.28	1	NC*				
Total	1.36	2	NC*				
<u>Leukemia</u>				<u>nyroid</u>			
Male	1.20	1	NC*	Male	0.33	0	NC*
Female	0.80	1	NC*	Female	0.83	0	NC*
Total	2.00	2	NC*	Total	1.15	0	NC*
Liver and Intr				teri, Corpus	and Uterus,	NOS_	
Male	0.47	1	NC*		• 00		
Female	0.18	0	NC*	Female	3.00	3	NC*
Total	0.65	1	NC*	u 04 /m			
Lung and Broi		17		ll Sites / Ty	_	CO	100
Male	9.10	17	187 #+	Male	55.51	60	108
Female	5.88	6	102	Female	48.00	49	102
Total	14.99	23	153	Total	103.50	109	105

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

MERRIMAC

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	$\mathbf{\underline{Exp}}$	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urina	<u>ry</u>		<u>M</u>	lelanoma of S	<u>Skin</u>		
Male	3.58	3	NC*	Male	2.00	2	NC*
Female	1.29	0	NC*	Female	1.64	1	NC*
Total	4.88	3	NC*	Total	3.64	3	NC*
Brain and Cen	tral Nervous S	<u>System</u>	<u>M</u>	<u>ultiple Myel</u>	<u>oma</u>		
Male	1.36	0	NC*	Male	0.65	0	NC*
Female	1.26	1	NC*	Female	0.59	0	NC*
Total	2.61	1	NC*	Total	1.24	0	NC*
Breast		Non-Hodgkin's Lymphoma					
Male	0.20	0	NC*	Male	2.81	3	NC*
Female	22.65	21	93	Female	2.41	0	NC*
Total	22.84	21	92	Total	5.23	3	NC*
Cervix Uteri		Oral Cavity and Pharynx					
				Male	2.69	4	NC*
Female	1.55	0	NC*	Female	1.13	0	NC*
				Total	3.82	4	NC*
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	9.49	7	74				
Female	8.53	10	117	Female	2.79	8	287 #+
Total	18.01	17	94				
Esophagus			<u>Pa</u>	<u>ancreas</u>			
Male	1.30	3	NC*	Male	1.35	1	NC*
Female	0.42	1	NC*	Female	1.37	0	NC*
Total	1.73	4	NC*	Total	2.73	1	NC*
<u>Hodgkin's Dis</u>	<u>ease</u>	<u>Prostate</u>					

Male	0.63	1	NC*	Male	20.67	22	106
Female	0.53	2	NC*				
Total	1.16	3	NC*				
Kidney and Re	nal Pelvis		St	omach_			
Male	2.23	7	315 #+	Male	1.59	0	NC*
Female	1.31	0	NC*	Female	0.92	1	NC*
Total	3.54	7	198	Total	2.52	1	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	1.43	2	NC*	Male	0.92	1	NC*
Female	0.39	0	NC*				
Total	1.82	2	NC*				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	1.52	1	NC*	Male	0.39	0	NC*
Female	1.13	3	NC*	Female	1.10	2	NC*
Total	2.65	4	NC*	Total	1.49	2	NC*
Liver and Intra	hepatic Bile l	<u>Ducts</u>	<u>U</u> 1	teri, Corpus	and Uterus,	NOS	
Male	0.62	0	NC*				
Female	0.27	0	NC*	Female	4.26	3	NC*
Total	0.89	0	NC*				
Lung and Brone	chus_		<u>A</u>]	ll Sites / Ty	pes_		
Male	12.04	6	50	Male	 72.72	69	95
Female	8.59	9	105	Female	69.00	64	93
Total	20.62	15	73	Total	141.72	133	94

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

METHUEN

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

Exp Obs SIR Exp Obs SIR

Bladder, Urinary Melanoma of Skin

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	32.24	46	143 #+	Male	16.08	9	56
Female	13.69	40 17	143 #+	Female	14.10	7	50
Total	45.92	63	137 #+	Total	30.18	16	53 ~-
Brain and Cen				ultiple Mye		10	33
Male Male	10.75	17	158	Male	5.79	5	86
Female	11.01	15	136	Female	6.06	8	132
Total	21.76	32	147 #+	Total	11.85	13	110
<u>Breast</u>	21110	V-			's Lymphoma		110
Male	1.69	4	NC*	Male	23.39	21	90
Female	205.13	212	103	Female	23.76	35	147 #+
Total	206.82	216	104	Total	47.16	56	119
Cervix Uteri			0	ral Cavity a	nd Pharynx		
				Male	21.10	23	109
Female	12.35	7	57	Female	10.56	8	76
				Total	31.66	31	98
Colon / Rectun	<u>1</u>		<u>O</u>	<u>varv</u>			
Male	- 85.59	114	133 ~+	·			
Female	92.43	79	85	Female	24.49	23	94
Total	178.02	193	108				
Esophagus			<u>Pa</u>	ancreas			
Male	10.80	15	139	Male	11.75	15	128
Female	4.59	10	218 #+	Female	14.46	17	118
Total	15.39	25	162 #+	Total	26.21	32	122
Hodgkin's Dis	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Male	4.84	6	124	Male	193.50	220	114
Female	4.08	3	NC*				
Total	8.91	9	101				
Kidney and Re	enal Pelvis		<u>St</u>	<u>omach</u>			
Male	18.48	19	103	Male	14.10	16	113
Female	12.44	24	193 ~+	Female	10.12	9	89
Total	30.92	43	139 #+	Total	24.22	25	103
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	11.60	13	112	Male	6.85	3	NC*
Female	3.46	7	202				
Total	15.06	20	133				
<u>Leukemia</u>			<u>T</u>	<u>hyroid</u>			
Male	12.78	17	133	Male	2.96	5	169
Female	10.69	13	122	Female	8.53	6	70
Total	23.47	30	128	Total	11.49	11	96
Liver and Intra	<u>-</u>			<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	5.23	6	115				
Female	2.72	3	NC*	Female	38.57	42	109
Total	7.96	9	113				
Lung and Bronchus			<u>A</u>]	ll Sites / Ty	<u>pes</u>		

Male	104.76	115	110	Male	638.89	743	116 ^+
Female	81.19	63	78 #-	Female	653.54	645	99
Total	185.95	178	96	Total	1292.42	1388	107 ~+

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

MIDDLEBOROUGH

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinar	<u>v</u>		<u>M</u>	elanoma of	<u>Skin</u>		
Male	10.84	5	46	Male	6.14	6	98
Female	4.49	5	111	Female	5.39	4	NC*
Total	15.33	10	65	Total	11.53	10	87
Brain and Cent	ral Nervous S	<u>System</u>	<u>M</u>	ultiple Mye	<u>loma</u>		
Male	4.30	4	NC*	Male	1.98	1	NC*
Female	4.11	2	NC*	Female	1.98	0	NC*
Total	8.41	6	71	Total	3.96	1	NC*
Breast			<u>N</u>	on-Hodgkin'	s Lymphoma	<u>a</u> _	
Male	0.60	1	NC*	Male	8.82	11	125
Female	72.39	66	91	Female	8.15	7	86
Total	72.99	67	92	Total	16.98	18	106
Cervix Uteri			<u>O</u> :	ral Cavity ar	nd Pharynx		
				Male	8.00	4	NC*
Female	5.09	7	138	Female	3.67	0	NC*
				Total	11.67	4	NC*
Colon / Rectum	_		<u>O</u>	<u>vary</u>			
Male	28.72	27	94				
Female	30.04	35	116	Female	8.93	9	101
Total	58.77	62	106				
Esophagus			<u>Pa</u>	ancreas_			

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	3.86	5	130	Male	4.06	9	222 #+		
Female	1.48	1	NC*	Female	4.66	3	NC*		
Total	5.34	6	112	Total	8.72	12	138		
Hodgkin's D	<u>isease</u>]	<u>Prostate</u>					
Male	2.18	3	NC*	Male	62.33	58	93		
Female	1.83	3	NC*						
Total	4.01	6	150						
Kidney and	Renal Pelvis	<u>vis</u> <u>Stomach</u>							
Male	6.72	9	134	Male	4.82	6	124		
Female	4.22	5	119	Female	3.34	2	NC*		
Total	10.93	14	128	Total	8.17	8	98		
<u>Larynx</u>			<u></u>	<u> </u>					
Male	4.20	3	NC*	Male	3.30	6	182		
Female	1.18	0	NC*						
Total	5.38	3	NC*						
<u>Leukemia</u>]	<u> Thyroid</u>					
Male	4.80	4	NC*	Male	1.27	2	NC*		
Female	3.93	3	NC*	Female	3.66	3	NC*		
Total	8.74	7	80	Total	4.93	5	101		
Liver and In	<u>trahepatic B</u>	ile Ducts	<u>]</u>	U <mark>teri, Corp</mark> u	ıs and Uter	us, NOS			
Male	1.86	3	NC*						
Female	0.91	0	NC*	Female	13.21	14	106		
Total	2.77	3	NC*						
Lung and Br	<u>onchus</u>	All Sites / Types							
Male	36.01	49	136 #+	Male	221.17	231	104		
Female	26.53	27	102	Female	226.09	213	94		
Total	62.55	76	122	Total	447.27	444	99		

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

MIDDLEFIELD

Cancer Incidence by Sex, 1990 - 1995

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary	<u>y</u>		$\underline{\mathbf{M}}$	lelanoma of S	<u>Skin</u>		
Male	0.29	1	NC*	Male	0.16	0	NC*
Female	0.09	0	NC*	Female	0.12	0	NC*
Total	0.38	1	NC*	Total	0.28	0	NC*
Brain and Centr	al Nervous S	<u>System</u>	$\underline{\mathbf{M}}$	<u>lultiple Myel</u>	<u>oma</u>		
Male	0.11	0	NC*	Male	0.05	0	NC*
Female	0.09	0	NC*	Female	0.04	0	NC*
Total	0.20	0	NC*	Total	0.09	0	NC*
Breast				on-Hodgkin's	s Lymphoma	<u>1</u>	
Male	0.02	0	NC*	Male	0.23	0	NC*
Female	1.62	3	NC*	Female	0.17	0	NC*
Total	1.64	3	NC*	Total	0.40	0	NC*
<u>Cervix Uteri</u>			<u>O</u>	ral Cavity an	d Pharynx		
				Male	0.22	0	NC*
Female	0.11	0	NC*	Female	0.08	0	NC*
				Total	0.30	0	NC*
Colon / Rectum			<u>O</u>	<u>vary</u>			
Male	0.75	0	NC*				
Female	0.59	0	NC*	Female	0.20	0	NC*
Total	1.35	0	NC*				
Esophagus			<u>Pa</u>	<u>ancreas</u>			
Male	0.10	0	NC*	Male	0.11	0	NC*
Female	0.03	0	NC*	Female	0.10	0	NC*
Total	0.13	0	NC*	Total	0.20	0	NC*
Hodgkin's Dise	ase_		<u>P</u> 1	<u>rostate</u>			
Male	0.05	0	NC*	Male	1.57	1	NC*
Female	0.04	0	NC*				
Total	0.09	0	NC*				
Kidney and Ren	al Pelvis		<u>St</u>	<u>omach</u>			
Male	0.18	0	NC*	Male	0.13	0	NC*
Female	0.09	0	NC*	Female	0.06	0	NC*
Total	0.27	0	NC*	Total	0.19	0	NC*
<u>Larynx</u>			\mathbf{T}	<u>estis</u>			
Male	0.11	0	NC*	Male	0.08	0	NC*
Female	0.03	0	NC*				
Total	0.14	0	NC*				
Leukemia				<u>hyroid</u>			
Male	0.12	0	NC*	Male	0.03	0	NC*
Female	0.08	0	NC*	Female	0.08	0	NC*
Total	0.20	0	NC*	Total	0.11	0	NC*

Liver and Intrahepatic Bile Ducts			<u>U</u> 1	<u>Uteri, Corpus and Uterus, NOS</u>				
Male	0.05	0	NC*					
Female	0.02	0	NC*	Female	0.31	0	NC*	
Total	0.07	0	NC*					
Lung and Bronchus			All Sites / Types					
Male	0.94	1	NC*	Male	5.73	3	NC*	
Female	0.60	0	NC*	Female	4.88	3	NC*	
Total	1.54	1	NC*	Total	10.61	6	57	

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

MIDDLETON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinaı	<u>ry</u>		<u>M</u>	elanoma of S	<u>Skin</u>		
Male	4.62	1	NC*	Male	2.38	3	NC*
Female	1.45	0	NC*	Female	1.77	1	NC*
Total	6.07	1	NC*	Total	4.15	4	NC*
Brain and Cent	ral Nervous S	<u>System</u>	<u>M</u>	ultiple Myel	<u>loma</u>		
Male	1.57	0	NC*	Male	0.84	0	NC*
Female	1.36	1	NC*	Female	0.66	0	NC*
Total	2.92	1	NC*	Total	1.50	0	NC*
Breast			<u>N</u>	on-Hodgkin's	s Lymphoma	<u>a</u> _	
Male	0.25	0	NC*	Male	3.40	4	NC*
Female	25.09	21	84	Female	2.66	0	NC*
Total	25.34	21	83	Total	6.06	4	NC*
Cervix Uteri			<u>O</u> :	ral Cavity an	nd Pharynx		
				Male	3.20	1	NC*
Female	1.63	2	NC*	Female	1.26	2	NC*
				Total	4.46	3	NC*

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>			
Male	12.28	8	65				
Female	9.53	7	73	Female	3.06	3	NC*
Total	21.81	15	69				
Esophagus				ncreas			
Male	1.61	1	NC*	Male	1.71	4	NC*
Female	0.48	1	NC*	Female	1.54	3	NC*
Total	2.09	2	NC*	Total	3.25	7	215
Hodgkin's Disc	<u>ease</u>		<u>Prostate</u>				
Male	0.68	3	NC*	Male	27.58	19	69
Female	0.53	0	NC*				
Total	1.21	3	NC*				
Kidney and Re	<u>nal Pelvis</u>		St	<u>omach</u>			
Male	2.75	2	NC*	Male	2.02	4	NC*
Female	1.46	3	NC*	Female	1.03	0	NC*
Total	4.21	5	119	Total	3.05	4	NC*
<u>Larynx</u>				<u>estis</u>			
Male	1.75	4	NC*	Male	0.97	3	NC*
Female	0.44	1	NC*				
Total	2.19	5	228				
<u>Leukemia</u>			<u>T</u>	<u>iyroid</u>			
Male	1.82	1	NC*	Male	0.44	1	NC*
Female	1.21	0	NC*	Female	1.13	1	NC*
Total	3.03	1	NC*	Total	1.57	2	NC*
Liver and Intra	hepatic Bile	<u>Ducts</u>	<u>U1</u>	t <mark>eri, Corpus</mark>	and Uterus,	NOS	
Male	0.77	1	NC*				
Female	0.30	0	NC*	Female	4.78	6	126
Total	1.07	1	NC*				
Lung and Bron	<u>chus</u>		<u>A</u> l	l Sites / Ty	pes		
Male	15.41	18	117	Male	92.49	85	92
Female	9.63	8	83	Female	76.40	65	85
Total	25.04	26	104	Total	168.88	150	89

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

MILFORD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urina	<u>ry</u>		<u>M</u>	<u>lelanoma of</u>	<u>Skin</u>		
Male	17.35	26	150	Male	9.30	6	65
Female	6.87	16	233 ~+	Female	8.00	7	88
Total	24.22	42	173 ~+	Total	17.29	13	75
Brain and Cen	<u>tral Nervous</u>	<u>System</u>	<u>M</u>	<u>ultiple Mye</u>	<u>eloma</u>		
Male	6.30	3	NC*	Male	3.15	2	NC*
Female	6.10	6	98	Female	3.06	5	163
Total	12.40	9	73	Total	6.21	7	113
<u>Breast</u>			<u>Ne</u>	<u>on-Hodgkin</u>	's Lymphom	<u>a</u>	
Male	0.93	2	NC*	Male	13.40	10	75
Female	110.83	119	107	Female	12.40	17	137
Total	111.77	121	108	Total	25.80	27	105
<u>Cervix Uteri</u>			<u>O</u> :	ral Cavity a	nd Pharynx		
				Male	12.16	9	74
Female	7.41	7	94	Female	5.61	3	NC*
				Total	17.77	12	68
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	46.02	40	87				
Female	45.93	48	105	Female	13.52	12	89
Total	91.95	88	96				
Esophagus			<u>Pa</u>	<u>ancreas</u>			
Male	6.01	6	100	Male	6.42	8	125
Female	2.28	0	NC*	Female	7.24	10	138
Total	8.29	6	72	Total	13.66	18	132
Hodgkin's Dis	<u>ease</u>		<u>Pı</u>	<u>rostate</u>			
Male	3.03	1	NC*	Male	101.80	104	102
Female	2.55	1	NC*				
Total	5.58	2	NC*				
Kidney and Re	-		<u>St</u>	<u>omach</u>			
Male	10.37	10	96	Male	7.66	8	104
Female	6.53	3	NC*	Female	5.03	11	219 #+
Total	16.90	13	77	Total	12.69	19	150
<u>Larynx</u>				<u>estis</u>			
Male	6.52	5	77	Male	4.55	6	132
Female	1.86	2	NC*				

Total	8.37	7	84				
Leukemia			<u>Tl</u>	<u>nyroid</u>			
Male	7.19	4	NC*	Male	1.84	0	NC*
Female	5.73	3	NC*	Female	5.23	5	96
Total	12.92	7	54	Total	7.06	5	71
Liver and Intra	ahepatic Bile	<u>Ducts</u>	<u>Uteri, Corpus and Uterus, NOS</u>				
Male	2.90	1	NC*				
Female	1.39	3	NC*	Female	20.61	13	63
Total	4.30	4	NC*				
Lung and Bron	<u>chus</u>		<u>A</u>]	ll Sites / Ty	<u>pes</u>		
Male	57.12	73	128 #+	Male	349.05	348	100
Female	42.26	31	73	Female	345.81	339	98
Total	99.37	104	105	Total	694.86	687	99

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} <= 0.05$ level
- ~ indicates statistical significance at the p <= 0.01 level, as well as at the p <= 0.05 level

MILLBURY

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urina	<u>ry</u>		<u>M</u>	elanoma of	<u>Skin</u>			
Male	10.01	17	170	Male	5.11	11	215 #+	
Female	3.93	3	NC*	Female	4.29	5	116	
Total	13.94	20	143	Total	9.40	16	170	
Brain and Cen	tral Nervous	<u>System</u>	Multiple Myeloma					
Male	3.37	6	178	Male	1.80	1	NC*	
Female	3.26	1	NC*	Female	1.74	1	NC*	
Total	6.64	7	105	Total	3.54	2	NC*	
Breast			Non-Hodgkin's Lymphoma					
Male	0.53	0	NC*	Male	7.37	6	81	
Female	60.94	50	82	Female	6.91	6	87	

^{* =} SIR and statistical significance not calculated when Obs < 5

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Total	61.47	50	81	Total	14.28	12	84
Cervix Uteri			<u>O</u> 1	<u>ral Cavity a</u>	<u>nd Pharynx</u>	ı	
				Male	6.70	2	NC*
Female	3.86	2	NC*	Female	3.12	8	257 #+
				Total	9.82	10	102
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	26.50	26	98				
Female	26.42	18	68	Female	7.34	2	NC*
Total	52.91	44	83				
Esophagus			<u>Pa</u>	ancreas			
Male	3.38	5	148	Male	3.64	0	NC*
Female	1.31	0	NC*	Female	4.11	2	NC*
Total	4.69	5	107	Total	7.76	2	NC*
Hodgkin's Disc	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Male	1.55	1	NC*	Male	58.76	49	83
Female	1.27	2	NC*				
Total	2.81	3	NC*				
Kidney and Re	enal Pelvis		<u>St</u>	omach_			
Male	5.76	6	104	Male	4.41	4	NC*
Female	3.59	3	NC*	Female	2.92	0	NC*
Total	9.35	9	96	Total	7.33	4	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	3.63	3	NC*	Male	2.26	6	265
Female	1.02	2	NC*				
Total	4.66	5	107				
<u>Leukemia</u>			<u>Tl</u>	<u>hyroid</u>			
Male	3.95	9	228 #+	Male	0.96	0	NC*
Female	3.13	3	NC*	Female	2.68	3	NC*
Total	7.09	12	169	Total	3.64	3	NC*
Liver and Intra	ahepatic Bile	<u>Ducts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus	, NOS	
Male	1.63	0	NC*				
Female	0.78	1	NC*	Female	11.35	9	79
Total	2.40	1	NC*				
Lung and Bron	<u>chus</u>		<u>A</u> 1	ll Sites / Ty	<u>pes</u>		
Male	32.28	30	93	Male	197.53	197	100
Female	23.21	29	125	Female	191.47	158	83 #-
Total	55.50	59	106	Total	389.00	355	91

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

MILLIS

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urinar	<u>.y</u>		<u>M</u>	<u>lelanoma of</u>	<u>Skin</u>			
Male	4.38	3	NC*	Male	2.62	5	191	
Female	1.36	2	NC*	Female	2.02	5	247	
Total	5.73	5	87	Total	4.64	10	215 #+	
Brain and Cent	<u>ral Nervous S</u>	<u>System</u>	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>			
Male	1.85	2	NC*	Male	0.81	2	NC*	
Female	1.50	0	NC*	Female	0.62	0	NC*	
Total	3.34	2	NC*	Total	1.43	2	NC*	
Breast			Non-Hodgkin's Lymphoma					
Male	0.25	0	NC*	Male	3.73	3	NC*	
Female	26.00	29	112	Female	2.67	4	NC*	
Total	26.24	29	111	Total	6.40	7	109	
<u>Cervix Uteri</u>			<u>O</u> 1	ral Cavity aı				
				Male	3.48	4	NC*	
Female	2.02	3	NC*	Female	1.27	1	NC*	
				Total	4.75	5	105	
Colon / Rectum	-			<u>vary</u>				
Male	11.67	15	128					
Female	8.82	9	102	Female	3.29	5	152	
Total	20.49	24	117					
Esophagus				ancreas				
Male	1.64	1	NC*	Male	1.71	1	NC*	
Female	0.43	2	NC*	Female	1.42	3	NC*	
Total	2.07	3	NC*	Total	3.13	4	NC*	
Hodgkin's Dise			· · · · · · · · · · · · · · · · · · ·	<u>rostate</u>				
Male	0.94	0	NC*	Male	26.02	32	123	
Female	0.73	2	NC*					
Total	1.67	2	NC*					
Kidney and Re				<u>omach</u>				
Male	2.88	2	NC*	Male	1.95	2	NC*	
Female	1.44	1	NC*	Female	0.97	1	NC*	

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Total	4.32	3	NC*	Total	2.91	3	NC*	
<u>Larynx</u>			<u>T</u>	<u>estis</u>				
Male	1.83	1	NC*	Male	1.46	4	NC*	
Female	0.43	0	NC*					
Total	2.26	1	NC*					
Leukemia	<u>mia </u>							
Male	1.99	1	NC*	Male	0.56	0	NC*	
Female	1.32	2	NC*	Female	1.47	1	NC*	
Total	3.31	3	NC*	Total	2.03	1	NC*	
<u>Liver and Intrahepatic Bile Ducts</u> <u>Uteri, Corpus and Intrahepatic Bile Ducts</u>					and Uterus,	NOS		
Male	0.79	3	NC*					
Female	0.29	0	NC*	Female	4.76	9	189	
Total	1.08	3	NC*					
Lung and Bron	nchus		<u>A</u>]	ll Sites / Ty	<u>pes</u>			
Male	15.36	18	117	Male	92.68	108	117	
Female	9.16	10	109	Female	77.36	96	124 #+	
Total	24.51	28	114	Total	170.04	204	120 #+	

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

MILLVILLE

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>		
Bladder, Urinar	<u>v</u>		Melanoma of Skin						
Male	1.15	2	NC*	Male	0.73	2	NC*		
Female	0.42	1	NC*	Female	0.65	0	NC*		
Total	1.57	3	NC*	Total	1.38	2	NC*		
Brain and Cent	ral Nervous S	<u>System</u>	<u>M</u>	ultiple Myel	<u>oma</u>				
Male	0.54	0	NC*	Male	0.21	0	NC*		
Female	0.50	0	NC*	Female	0.19	0	NC*		

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Total	1.03	0	NC*	Total	0.40	0	NC*
Breast			<u>N</u>	on-Hodgkin	's Lymphoma	<u>a</u>	
Male	0.07	0	NC*	Male	1.05	1	NC*
Female	8.12	14	172	Female	0.85	0	NC*
Total	8.19	14	171	Total	1.89	1	NC*
Cervix Uteri			<u>O</u> :	ral Cavity a	nd Pharynx		
				Male	0.93	0	NC*
Female	0.67	0	NC*	Female	0.40	1	NC*
				Total	1.33	1	NC*
Colon / Rectum	_		<u>O</u>	<u>vary</u>			
Male	3.07	2	NC*				
Female	2.70	3	NC*	Female	1.05	1	NC*
Total	5.76	5	87				
Esophagus			<u>Pa</u>	ancreas			
Male	0.43	0	NC*	Male	0.45	0	NC*
Female	0.13	0	NC*	Female	0.44	0	NC*
Total	0.56	0	NC*	Total	0.89	0	NC*
Hodgkin's Dise	ease		<u>P</u> 1	<u>rostate</u>			
Male	0.30	0	NC*	Male	6.77	5	74
Female	0.26	0	NC*				
Total	0.56	0	NC*				
Kidney and Re	nal Pelvis		<u>St</u>	<u>omach</u>			
Male	0.77	0	NC*	Male	0.52	0	NC*
Female	0.46	0	NC*	Female	0.29	0	NC*
Total	1.23	0	NC*	Total	0.81	0	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.48	0	NC*	Male	0.48	0	NC*
Female	0.13	0	NC*				
Total	0.61	0	NC*				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	0.57	2	NC*	Male	0.17	0	NC*
Female	0.44	0	NC*	Female	0.50	0	NC*
Total	1.00	2	NC*	Total	0.67	0	NC*
Liver and Intra	<u>hepatic Bile l</u>	<u>Ducts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	0.21	1	NC*				
Female	0.09	0	NC*	Female	1.48	1	NC*
Total	0.30	1	NC*				
Lung and Brone	<u>chus</u>		$\underline{\mathbf{A}}$	ll Sites / Typ	<u>pes</u>		
Male	4.01	4	NC*	Male	24.78	20	81
Female	2.89	1	NC*	Female	24.35	24	99
Total	6.90	5	72	Total	49.13	44	90

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} <= 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

MILTON

Expected and Observed Case Counts, with Standardized Incidence Ratios

Cancer Incidence by Sex, 1990 - 1995

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urina	<u>ry</u>		<u>M</u>	<u>lelanoma of</u>	Skin				
Male	22.68	32	141	Male	10.84	18	166		
Female	9.23	15	163	Female	9.32	18	193 #+		
Total	31.91	47	147 #+	Total	20.16	36	179 ~+		
Brain and Cen	<u>tral Nervous</u>	<u>System</u>	$\underline{\mathbf{M}}$	ultiple Mye	<u>eloma</u>				
Male	7.06	9	127	Male	4.06	4	NC*		
Female	7.24	10	138	Female	4.07	6	147		
Total	14.30	19	133	Total	8.13	10	123		
Breast			No	on-Hodgkin	's Lymphom	<u>a</u>			
Male	1.18	1	NC*	Male	15.75	15	95		
Female	136.83	192	140 ^+	Female	15.87	19	120		
Total	138.01	193	140 ^+	Total	31.62	34	108		
<u>Cervix Uteri</u>			Oral Cavity and Pharynx						
				Male	14.28	10	70		
Female	8.03	12	149	Female	7.05	6	85		
				Total	21.33	16	75		
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>					
Male	60.02	85	142 ~+						
Female	62.44	64	103	Female	16.26	11	68		
Total	122.46	149	122 #+						
Esophagus			<u>Pa</u>	<u>ancreas</u>					
Male	7.45	8	107	Male	8.11	7	86		
Female	3.09	0	NC*	Female	9.72	10	103		
Total	10.54	8	76	Total	17.82	17	95		
Hodgkin's Dis	<u>ease</u>		<u>Pı</u>	<u>rostate</u>					
Male	2.99	3	NC*	Male	134.27	181	135 ^+		

Female	2.58	2	NC*				
Total	5.57	5	90				
Kidney and Re	enal Pelvis		<u>St</u>	<u>omach</u>			
Male	12.56	9	72	Male	9.91	8	81
Female	8.26	7	85	Female	6.87	14	204 #+
Total	20.83	16	77	Total	16.78	22	131
<u>Larynx</u>			<u>Te</u>	<u>estis</u>			
Male	7.91	11	139	Male	4.04	5	124
Female	2.30	5	217				
Total	10.21	16	157				
Leukemia			<u>Tł</u>	<u>iyroid</u>			
Male	8.63	4	NC*	Male	1.88	1	NC*
Female	7.09	4	NC*	Female	5.51	9	163
Total	15.72	8	51	Total	7.39	10	135
Liver and Intr	ahepatic Bile	<u>Ducts</u>	<u>U1</u>	t <mark>eri, Corpus</mark>	and Uterus	s, NOS	
Male	3.58	5	140				
Female	1.81	1	NC*	Female	25.71	31	121
Total	5.39	6	111				
Lung and Broi	<u>nchus</u>		<u>A</u> l	ll Sites / Ty	pes		
Male	71.96	63	88	Male	439.57	505	115 ~+
Female	53.83	50	93	Female	436.06	521	119 ^+
Total	125.79	113	90	Total	875.63	1026	117 ^+

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

MONROE

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		<u>Exp</u>	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary			<u>Me</u>	elanoma of S	<u>Skin</u>		
Male	0.15	0	NC*	Male	0.07	0	NC*

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	0.03	0	NC*	Female	0.04	0	NC*
Total	0.19	0	NC*	Total	0.11	0	NC*
Brain and Cen	tral Nervous S	<u>vstem</u>	<u>M</u>	<u>lultiple Myel</u>	<u>oma</u>		
Male	0.04	0	NC*	Male	0.03	0	NC*
Female	0.03	0	NC*	Female	0.01	0	NC*
Total	0.07	0	NC*	Total	0.04	0	NC*
Breast			<u>N</u>	on-Hodgkin's	s Lymphoma	<u>l</u>	
Male	0.01	0	NC*	Male	0.10	0	NC*
Female	0.55	1	NC*	Female	0.06	0	NC*
Total	0.56	1	NC*	Total	0.16	0	NC*
<u>Cervix Uteri</u>			<u>O</u> :	<u>ral Cavity an</u>	<u>d Pharynx</u>		
				Male	0.09	0	NC*
Female	0.03	0	NC*	Female	0.03	0	NC*
				Total	0.12	0	NC*
Colon / Rectum	<u>1</u>			<u>vary</u>			
Male	0.40	0	NC*				
Female	0.21	0	NC*	Female	0.07	0	NC*
Total	0.62	0	NC*				
Esophagus			<u>Pa</u>	ancreas			
Male	0.05	0	NC*	Male	0.05	0	NC*
Female	0.01	0	NC*	Female	0.03	0	NC*
Total	0.06	0	NC*	Total	0.09	0	NC*
Hodgkin's Dis	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Male	0.02	0	NC*	Male	0.90	0	NC*
Female	0.01	0	NC*				
Total	0.03	0	NC*				
Kidney and Re	enal Pelvis			<u>omach</u>			
Male	0.08	0	NC*	Male	0.07	0	NC*
Female	0.03	0	NC*	Female	0.02	0	NC*
Total	0.11	0	NC*	Total	0.09	0	NC*
<u>Larynx</u>				<u>estis</u>			
Male	0.05	0	NC*	Male	0.02	0	NC*
Female	0.01	0	NC*				
Total	0.06	0	NC*				
<u>Leukemia</u>			_	<u>hyroid</u>			
Male	0.05	0	NC*	Male	0.01	0	NC*
Female	0.03	0	NC*	Female	0.02	0	NC*
Total	0.08	0	NC*	Total	0.03	0	NC*
Liver and Intra	_			teri, Corpus	and Uterus,	NOS_	
Male	0.02	0	NC*		0		
Female	0.01	0	NC*	Female	0.11	1	NC*
Total	0.03	0	NC*				
Lung and Bron				ll Sites / Typ			
Male	0.47	1	NC*	Male	2.88	1	NC*

Female	0.21	0	NC*	Female	1.68	2	NC*
Total	0.68	1	NC*	Total	4.56	3	NC*

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

MONSON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urina	<u>ry</u>		<u>M</u>	elanoma of S	<u>Skin</u>			
Male	5.55	6	108	Male	3.04	6	197	
Female	1.93	0	NC*	Female	2.48	2	NC*	
Total	7.47	6	80	Total	5.52	8	145	
Brain and Cen	tral Nervous S	<u>System</u>	<u>M</u>	ultiple Myel	<u>loma</u>			
Male	2.07	3	NC*	Male	1.02	1	NC*	
Female	1.89	0	NC*	Female	0.88	2	NC*	
Total	3.96	3	NC*	Total	1.89	3	NC*	
Breast			Non-Hodgkin's Lymphoma					
Male	0.30	1	NC*	Male	4.34	3	NC*	
Female	34.09	38	111	Female	3.60	3	NC*	
Total	34.40	39	113	Total	7.94	6	76	
Cervix Uteri			<u>O</u> :	ral Cavity an	nd Pharynx			
				Male	4.06	3	NC*	
Female	2.35	1	NC*	Female	1.70	1	NC*	
				Total	5.76	4	NC*	
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>				
Male	14.77	11	74					
Female	12.63	17	135	Female	4.21	2	NC*	
Total	27.40	28	102					
Esophagus			<u>Pa</u>	ancreas				
Male	1.99	1	NC*	Male	2.10	2	NC*	

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	0.63	0	NC*	Female	2.03	3	NC*
Total	2.62	1	NC*	Total	4.13	5	121
Hodgkin's Disc	ease		<u>P</u> 1	<u>rostate</u>			
Male	0.97	1	NC*	Male	33.01	30	91
Female	0.80	0	NC*				
Total	1.77	1	NC*				
Kidney and Re	nal Pelvis		St	omach_			
Male	3.44	2	NC*	Male	2.44	1	NC*
Female	1.96	1	NC*	Female	1.37	0	NC*
Total	5.40	3	NC*	Total	3.81	1	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	2.18	1	NC*	Male	1.44	2	NC*
Female	0.59	2	NC*				
Total	2.77	3	NC*				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	2.34	4	NC*	Male	0.60	1	NC*
Female	1.69	3	NC*	Female	1.66	1	NC*
Total	4.03	7	174	Total	2.26	2	NC*
Liver and Intra	hepatic Bile I	<u>Ducts</u>	<u>U</u> 1	teri, Corpus	and Uterus,	NOS	
Male	0.95	0	NC*				
Female	0.40	0	NC*	Female	6.41	12	187
Total	1.36	0	NC*				
Lung and Bron	<u>chus</u>		<u>A</u>	ll Sites / Ty	<u>pes</u>		
Male	18.87	18	95	Male	113.57	103	91
Female	12.79	19	149	Female	103.39	117	113
Total	31.66	37	117	Total	216.96	220	101

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

MONTAGUE

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

	Exp	Obs	SIR		Exp	<u>Obs</u>	SIR	
Bladder, Urinar	<u>y</u> _		<u>M</u>	<u>lelanoma of</u>	<u>Skin</u>			
Male	6.83	10	146	Male	3.35	3	NC*	
Female	2.47	3	NC*	Female	2.76	4	NC*	
Total	9.30	13	140	Total	6.11	7	115	
Brain and Cent	<u>ral Nervous S</u>	<u>System</u>	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>			
Male	2.22	0	NC*	Male	1.22	0	NC*	
Female	2.16	3	NC*	Female	1.11	1	NC*	
Total	4.38	3	NC*	Total	2.33	1	NC*	
Breast			No	on-Hodgkin'	s Lymphoma	<u>L</u>		
Male	0.36	0	NC*	Male	4.88	4	NC*	
Female	39.35	47	119	Female	4.41	6	136	
Total	39.71	47	118	Total	9.30	10	108	
<u>Cervix Uteri</u>			Oral Cavity and Pharynx					
				Male	4.41	11	249 #+	
Female	2.50	2	NC*	Female	2.02	1	NC*	
				Total	6.43	12	187	
Colon / Rectum	<u>.</u>		<u>O</u>	<u>vary</u>				
Male	18.15	27	149					
Female	16.45	29	176 ~+	Female	4.76	14	294 ^+	
Total	34.60	56	162 ~+					
Esophagus			<u>Pa</u>	ancreas				
Male	2.28	2	NC*	Male	2.49	4	NC*	
Female	0.83	1	NC*	Female	2.62	8	306 #+	
Total	3.10	3	NC*	Total	5.11	12	235 #+	
Hodgkin's Dise	ase_		<u>Pı</u>	<u>rostate</u>				
Male	0.98	0	NC*	Male	41.53	35	84	
Female	0.84	0	NC*					
Total	1.82	0	NC*					
Kidney and Rei	nal Pelvis		<u>St</u>	<u>omach</u>				
Male	3.89	7	180	Male	2.98	1	NC*	
Female	2.37	2	NC*	Female	1.78	1	NC*	
Total	6.26	9	144	Total	4.75	2	NC*	
<u>Larynx</u>			<u>Te</u>	<u>estis</u>				
Male	2.45	4	NC*	Male	1.38	4	NC*	
Female	0.68	0	NC*					
Total	3.13	4	NC*					
<u>Leukemia</u>			<u>Tl</u>	<u>nyroid</u>				
Male	2.66	4	NC*	Male	0.61	0	NC*	
Female	2.01	5	248	Female	1.74	2	NC*	
Total	4.67	9	193	Total	2.35	2	NC*	
Liver and Intra	hepatic Bile	<u>Ducts</u>	<u>U</u> 1	teri, Corpus	and Uterus,	NOS_		
Male	1.10	1	NC*					

0.51	0	NC*	Female	7.46	9	121
1.61	1	NC*				
<u>nchus</u>		<u>A</u>]	ll Sites / Ty	<u>pes</u>		
22.26	32	144	Male	135.35	161	119 #+
15.56	20	129	Female	123.41	164	133 ^+
37.82	52	137 #+	Total	258.75	325	126 ^+
	1.61 nchus 22.26 15.56	1.61 1 nchus 22.26 32 15.56 20	1.61 1 NC* nchus Al 22.26 32 144 15.56 20 129	1.61 1 NC* nchus All Sites / Ty 22.26 32 144 Male 15.56 20 129 Female	1.61 1 NC* nchus All Sites / Types 22.26 32 144 Male 135.35 15.56 20 129 Female 123.41	1.61 1 NC* nchus 22.26 32 144 Male 135.35 161 15.56 20 129 Female 123.41 164

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

MONTEREY

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	SIR	
Bladder, Urinary	_		<u>M</u>	<u>lelanoma of S</u>	<u>Skin</u>			
Male	0.80	1	NC*	Male	0.39	0	NC*	
Female	0.22	1	NC*	Female	0.27	1	NC*	
Total	1.02	2	NC*	Total	0.67	1	NC*	
Brain and Centra	al Nervous S	<u>System</u>	Multiple Myeloma					
Male	0.26	0	NC*	Male	0.14	0	NC*	
Female	0.21	1	NC*	Female	0.10	0	NC*	
Total	0.46	1	NC*	Total	0.25	0	NC*	
Breast			Non-Hodgkin's Lymphoma					
Male	0.04	0	NC*	Male	0.57	2	NC*	
Female	3.91	2	NC*	Female	0.41	0	NC*	
Total	3.96	2	NC*	Total	0.97	2	NC*	
Cervix Uteri			<u>O</u> :	ral Cavity an	d Pharynx			
				Male	0.53	0	NC*	
Female	0.25	0	NC*	Female	0.20	0	NC*	
				Total	0.72	0	NC*	
Colon / Rectum			<u>O</u>	<u>vary</u>				
Male	2.12	2	NC*					

^{* =} SIR and statistical significance not calculated when Obs < 5

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	1.45	1	NC*	Female	0.48	1	NC*
Total	3.57	3	NC*				
Esophagus			<u>Pa</u>	ancreas			
Male	0.27	0	NC*	Male	0.29	0	NC*
Female	0.07	0	NC*	Female	0.23	1	NC*
Total	0.34	0	NC*	Total	0.52	1	NC*
Hodgkin's Dise	ase		<u>P1</u>	<u>rostate</u>			
Male	0.11	0	NC*	Male	4.77	6	126
Female	0.08	0	NC*				
Total	0.19	0	NC*				
Kidney and Rei	<u>nal Pelvis</u>		<u>St</u>	<u>omach</u>			
Male	0.46	0	NC*	Male	0.35	0	NC*
Female	0.22	0	NC*	Female	0.16	0	NC*
Total	0.68	0	NC*	Total	0.51	0	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.29	0	NC*	Male	0.15	1	NC*
Female	0.07	0	NC*				
Total	0.36	0	NC*				
Leukemia			<u>Tl</u>	<u>nyroid</u>			
Male	0.31	0	NC*	Male	0.07	0	NC*
Female	0.18	1	NC*	Female	0.17	0	NC*
Total	0.49	1	NC*	Total	0.24	0	NC*
Liver and Intra	<u>hepatic Bile I</u>	<u>Ducts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	0.13	0	NC*				
Female	0.05	0	NC*	Female	0.75	0	NC*
Total	0.17	0	NC*				
Lung and Brono	<u>chus</u>		$\underline{\mathbf{A}}$	ll Sites / Typ	<u>oes</u>		
Male	2.60	1	NC*	Male	15.73	13	83
Female	1.48	0	NC*	Female	11.79	9	76
Total	4.08	1	NC*	Total	27.52	22	80

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

MONTGOMERY

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR
Bladder, Urinar	_			<u>lelanoma of S</u>			
Male	0.57	0	NC*	Male	0.31	0	NC*
Female	0.20	0	NC*	Female	0.25	0	NC*
Total	0.77	0	NC*	Total	0.56	0	NC*
Brain and Cent				<u>lultiple Myel</u>			
Male	0.21	0	NC*	Male	0.11	0	NC*
Female	0.19	0	NC*	Female	0.09	0	NC*
Total	0.40	0	NC*	Total	0.20	0	NC*
Breast				on-Hodgkin's	<u>S Lymphoma</u>	 -	
Male	0.03	0	NC*	Male	0.44	0	NC*
Female	3.45	1	NC*	Female	0.37	0	NC*
Total	3.48	1	NC*	Total	0.81	0	NC*
<u>Cervix Uteri</u>			<u>O</u> :	<u>ral Cavity an</u>	<u>d Pharynx</u>		
				Male	0.44	0	NC*
Female	0.23	0	NC*	Female	0.17	0	NC*
				Total	0.61	0	NC*
Colon / Rectum	ı		<u>O</u>	<u>vary</u>			
Male	1.54	2	NC*				
Female	1.31	1	NC*	Female	0.42	1	NC*
Total	2.85	3	NC*				
Esophagus			<u>Pa</u>	<u>ancreas</u>			
Male	0.21	0	NC*	Male	0.22	1	NC*
Female	0.07	0	NC*	Female	0.21	1	NC*
Total	0.28	0	NC*	Total	0.43	2	NC*
Hodgkin's Dise	ase		<u>P</u> 1	<u>rostate</u>			
Male	0.09	0	NC*	Male	3.55	2	NC*
Female	0.07	0	NC*				
Total	0.17	0	NC*				
Kidney and Ren	nal Pelvis		<u>St</u>	<u>omach</u>			
Male	0.37	0	NC*	Male	0.25	0	NC*
Female	0.20	0	NC*	Female	0.14	0	NC*
Total	0.57	0	NC*	Total	0.40	0	NC*
Larynx			<u>T</u>	<u>estis</u>			
Male	0.24	0	NC*	Male	0.13	0	NC*
Female	0.06	0	NC*				
Total	0.30	0	NC*				
Leukemia			<u>T</u>	<u>hyroid</u>			

Male	0.24	0	NC*	Male	0.06	0	NC*
Female	0.17	0	NC*	Female	0.16	1	NC*
Total	0.41	0	NC*	Total	0.22	1	NC*
Liver and Intra	hepatic Bile E	<u>Oucts</u>	<u>U</u> 1	teri, Corpus	and Uterus,	NOS_	
Male	0.10	0	NC*				
Female	0.04	0	NC*	Female	0.65	1	NC*
Total	0.14	0	NC*				
Lung and Brono	<u>chus</u>		<u>A</u>]	ll Sites / Typ	<u>oes</u>		
Male	2.04	1	NC*	Male	11.98	6	50
Female	1.28	0	NC*	Female	10.48	6	57
Total	3.32	1	NC*	Total	22.46	12	53 #-

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} <= 0.05$ level
- ~ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

MOUNT WASHINGTON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinar	<u>v</u>		<u>M</u>	elanoma of S	<u>Skin</u>		
Male	0.13	0	NC*	Male	0.06	0	NC*
Female	0.05	0	NC*	Female	0.05	0	NC*
Total	0.18	0	NC*	Total	0.11	0	NC*
Brain and Cent	<u>ral Nervous S</u>	<u>System</u>	<u>M</u>	ultiple Myel	<u>oma</u>		
Male	0.04	0	NC*	Male	0.02	0	NC*
Female	0.04	1	NC*	Female	0.02	0	NC*
Total	0.08	1	NC*	Total	0.04	0	NC*
Breast			<u>N</u>	on-Hodgkin's	s Lymphoma	<u>1</u>	
Male	0.01	0	NC*	Male	0.09	0	NC*
Female	0.71	0	NC*	Female	0.08	0	NC*
Total	0.72	0	NC*	Total	0.17	0	NC*
<u>Cervix Uteri</u>			<u>O</u> :	ral Cavity an	d Pharynx		

^{* =} SIR and statistical significance not calculated when Obs < 5

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

				Male	0.09	0	NC*
Female	0.04	0	NC*	Female	0.04	0	NC*
				Total	0.13	0	NC*
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	0.34	1	NC*	. _			
Female	0.32	1	NC*	Female	0.08	0	NC*
Total	0.66	2	NC*				
Esophagus			<u>Pa</u>	ancreas			
Male	0.05	0	NC*	Male	0.05	0	NC*
Female	0.02	0	NC*	Female	0.05	0	NC*
Total	0.06	0	NC*	Total	0.10	0	NC*
Hodgkin's Dis	sease_		<u>P1</u>	<u>rostate</u>			
Male	0.02	0	NC*	Male	0.72	0	NC*
Female	0.01	0	NC*				
Total	0.03	0	NC*				
Kidney and Ro	enal Pelvis		<u>St</u>	<u>omach</u>			
Male	0.07	0	NC*	Male	0.06	0	NC*
Female	0.04	0	NC*	Female	0.03	0	NC*
Total	0.12	0	NC*	Total	0.09	0	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	0.05	0	NC*	Male	0.02	0	NC*
Female	0.01	0	NC*				
Total	0.06	0	NC*				
<u>Leukemia</u>			<u>Tl</u>	<u>nyroid</u>			
Male	0.05	0	NC*	Male	0.01	0	NC*
Female	0.03	0	NC*	Female	0.03	0	NC*
Total	0.08	0	NC*	Total	0.04	0	NC*
Liver and Intr	<u>ahepatic Bile D</u>	<u>ucts</u>		teri, Corpus	and Uterus, 1	NOS_	
Male	0.02	0	NC*				
Female	0.01	0	NC*	Female	0.14	0	NC*
Total	0.03	0	NC*				
Lung and Bron				ll Sites / Typ	<u>es</u>		
Male	0.41	0	NC*	Male	2.48	1	NC*
Female	0.29	0	NC*	Female	2.24	2	NC*
Total	0.70	0	NC*	Total	4.72	3	NC*

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

NAHANT

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	$\underline{\mathbf{Exp}}$	<u>Obs</u>	<u>SIR</u>		$\mathbf{\underline{Exp}}$	<u>Obs</u>	<u>SIR</u>	
Bladder, Urinar	<u>y</u>		<u>M</u>	elanoma of	<u>Skin</u>			
Male	3.82	2	NC*	Male	1.83	1	NC*	
Female	1.41	0	NC*	Female	1.40	2	NC*	
Total	5.23	2	NC*	Total	3.23	3	NC*	
Brain and Cent	ral Nervous	<u>System</u>	<u>M</u>	ultiple Mye	<u>loma</u>			
Male	1.15	0	NC*	Male	0.68	0	NC*	
Female	1.07	2	NC*	Female	0.62	1	NC*	
Total	2.22	2	NC*	Total	1.30	1	NC*	
Breast			<u>No</u>	<u>on-Hodgkin'</u>	s Lymphoma	<u>l</u>		
Male	0.20	0	NC*	Male	2.63	1	NC*	
Female	20.69	19	92	Female	2.40	3	NC*	
Total	20.89	19	91	Total	5.03	4	NC*	
<u>Cervix Uteri</u>		Oral Cavity and Pharynx						
				Male	2.43	1	NC*	
Female	1.19	4	NC*	Female	1.07	0	NC*	
				Total	3.50	1	NC*	
Colon / Rectum	_		<u>O</u>	<u>vary</u>				
Male	10.10	14	139					
Female	9.51	8	84	Female	2.45	5	204	
Total	19.61	22	112					
Esophagus			<u>Pa</u>	ancreas				
Male	1.26	4	NC*	Male	1.37	1	NC*	
Female	0.47	0	NC*	Female	1.48	1	NC*	
Total	1.73	4	NC*	Total	2.85	2	NC*	
Hodgkin's Dise	ease_		<u>Pr</u>	<u>rostate</u>				
Male	0.48	1	NC*	Male	22.51	27	120	
Female	0.37	0	NC*					
Total	0.85	1	NC*					
Kidney and Re	<u>nal Pelvis</u>		<u>St</u>	<u>omach</u>				
Male	2.11	1	NC*	Male	1.67	0	NC*	
Female	1.25	2	NC*	Female	1.05	0	NC*	
Total	3.35	3	NC*	Total	2.72	0	NC*	
<u>Larynx</u>			<u>Te</u>	<u>estis</u>				

[~] indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	1.34	2	NC*	Male	0.66	3	NC*
Female	0.35	0	NC*				
Total	1.69	2	NC*				
Leukemia			<u>Tł</u>	<u>iyroid</u>			
Male	1.40	3	NC*	Male	0.31	0	NC*
Female	1.05	1	NC*	Female	0.81	1	NC*
Total	2.45	4	NC*	Total	1.12	1	NC*
Liver and Intra	<u>U1</u>	teri, Corpus	and Uterus,	NOS			
		_	3.7.00.1.				
Male	0.60	0	NC*				
Male Female	0.60 0.27	0	NC* NC*	Female	3.90	3	NC*
		_		Female	3.90	3	NC*
Female	0.27 0.87	0	NC* NC*	Female		3	NC*
Female Total	0.27 0.87	0	NC* NC*			3 71	NC*
Female Total Lung and Bron	0.27 0.87 achus	0	NC* NC* <u>Al</u>	ll Sites / Ty	<u>pes</u>		
Female Total Lung and Bron Male	0.27 0.87 achus 12.11	0 0 7	NC* NC* <u>Al</u> 58	l <mark>l Sites / Ty</mark> Male	pes_ 73.71	71	96

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

NANTUCKET

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	SIR
Bladder, Urinar	<u>v</u>		Melanoma of Skin				
Male	4.60	6	130	Male	2.46	7	284 #+
Female	1.78	2	NC*	Female	2.04	2	NC*
Total	6.38	8	125	Total	4.51	9	200
Brain and Cent	ral Nervous S	<u>System</u>	Multiple Myeloma				
Male	1.65	4	NC*	Male	0.83	2	NC*
Female	1.54	3	NC*	Female	0.79	1	NC*
Total	3.19	7	219	Total	1.62	3	NC*
Breast			N	on-Hodgkin's	s Lymphoma	ı	

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	0.25	0	NC*	Male	3.54	6	169
Female	28.35	29	102	Female	3.19	5	157
Total	28.59	29	101	Total	6.73	11	163
Cervix Uteri			<u>O</u> 1	ral Cavity a	nd Pharynx		
				Male	3.22	4	NC*
Female	1.89	3	NC*	Female	1.44	1	NC*
				Total	4.66	5	107
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	12.20	17	139				
Female	11.93	14	117	Female	3.45	1	NC*
Total	24.13	31	128				
Esophagus			<u>Pa</u>	ancreas			
Male	1.59	6	377 #+	Male	1.70	3	NC*
Female	0.59	1	NC*	Female	1.87	3	NC*
Total	2.18	7	321 #+	Total	3.57	6	168
Hodgkin's Dis	<u>ease</u>		<u>Pr</u>	<u>rostate</u>			
Male	0.80	2	NC*	Male	27.01	40	148 #+
Female	0.64	0	NC*				
Total	1.44	2	NC*				
Kidney and Re	enal Pelvis		St	<u>omach</u>			
Male	2.73	0	NC*	Male	2.03	0	NC*
Female	1.67	3	NC*	Female	1.31	2	NC*
Total	4.40	3	NC*	Total	3.35	2	NC*
<u>Larynx</u>			Te	<u>estis</u>			
Male	1.73	2	NC*	 Male	1.21	1	NC*
Female	0.47	1	NC*				
Total	2.20	3	NC*				
Leukemia			<u>Tì</u>	<u>nyroid</u>			
Male	1.89	3	NC*	Male	0.48	0	NC*
Female	1.45	1	NC*	Female	1.33	2	NC*
Total	3.34	4	NC*	Total	1.81	2	NC*
Liver and Intra	ahepatic Bile	Ducts	<u>U1</u>	teri, Corpus	and Uterus	NOS	
Male	0.77	0	NC*				
Female	0.36	0	NC*	Female	5.26	9	171
Total	1.12	0	NC*				
Lung and Bron	chus		<u>A</u> l	ll Sites / Ty	<u>pes</u>		
Male	15.10	13	86	Male	92.42	126	136 ~+
Female	10.79	10	93	Female	88.66	97	109
Total	25.89	23	89	Total	181.08	223	123 ~+

 $\mathbf{Exp} = \text{expected case count}$, based on the Massachusetts average age-specific incidence rates for this cancer $\mathbf{Obs} = \text{observed case count}$

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

NATICK

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urina	ry		$\underline{\mathbf{M}}$	<u>lelanoma of</u>	Skin		
Male	22.50	23	102	Male	12.03	13	108
Female	8.69	10	115	Female	10.40	9	87
Total	31.19	33	106	Total	22.42	22	98
Brain and Central Nervous System Multiple My					eloma_		
Male	8.04	2	NC*	Male	4.08	6	147
Female	7.81	11	141	Female	3.91	4	NC*
Total	15.85	13	82	Total	7.98	10	125
Breast			No	<u>on-Hodgkin</u>	's Lymphoma	<u>a</u>	
Male	1.21	3	NC*	Male	17.26	16	93
Female	144.53	158	109	Female	15.77	23	146
Total	145.74	161	110	Total	33.03	39	118
<u>Cervix Uteri</u>			<u>O</u> :	<u>ral Cavity a</u>	nd Pharynx		
				Male	15.92	27	170 #+
Female	9.69	11	114	Female	7.29	7	96
				Total	23.21	34	146 #+
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	59.86	65	109				
Female	57.57	56	97	Female	17.63	23	130
Total	117.43	121	103				
Esophagus			<u>Pa</u>	ancreas			
Male	7.88	4	NC*	Male	8.43	11	130
Female	2.87	4	NC*	Female	9.14	13	142
Total	10.75	8	74	Total	17.58	24	137
Hodgkin's Dis	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Male	3.78	3	NC*	Male	135.04	147	109
Female	3.21	5	156				
Total	6.99	8	115				

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Kidney and Re	enal Pelvis		<u>St</u>	<u>omach</u>			
Male	13.57	5	37 #-	Male	9.90	5	51
Female	8.40	11	131	Female	6.28	6	96
Total	21.97	16	73	Total	16.17	11	68
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	8.61	6	70	Male	5.69	2	NC*
Female	2.47	3	NC*				
Total	11.08	9	81				
Leukemia			<u>T</u>	<u>nyroid</u>			
Male	9.14	8	87	Male	2.35	1	NC*
Female	7.14	13	182	Female	6.77	10	148
Total	16.28	21	129	Total	9.12	11	121
Liver and Intra	ahepatic Bile	Ducts	<u>U</u> 1	teri, Corpus	and Uterus,	NOS	
Male	3.79	2	NC*				
Female	1.76	1	NC*	Female	27.09	17	63
Total	5.56	3	NC*				
Lung and Bron	<u>ichus</u>		<u>A</u>	ll Sites / Ty	<u>pes</u>		
Male	75.46	80	106	Male	456.66	459	101
Female	54.92	60	109	Female	445.40	484	109
Total	130.38	140	107	Total	902.06	943	105

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

NEEDHAM

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	\mathbf{Exp}	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urina	<u>ry</u>		$\underline{\mathbf{N}}$	<u> Ielanoma of</u>	<u>Skin</u>		
Male	25.09	31	124	Male	12.16	20	164 #+
Female	10.53	9	85	Female	10.47	11	105
Total	35.63	40	112	Total	22.63	31	137

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Brain and Cen	tral Nervous	<u>System</u>	Multiple Myeloma				
Male	7.85	8	102	Male	4.49	4	NC*
Female	8.08	11	136	Female	4.62	5	108
Total	15.93	19	119	Total	9.11	9	99
Breast			<u>N</u>	on-Hodgkin	's Lymphom	<u>a</u>	
Male	1.31	1	NC*	Male	17.45	20	115
Female	154.53	182	118 #+	Female	17.93	20	112
Total	155.84	183	117 #+	Total	35.38	40	113
<u>Cervix Uteri</u>			<u>O</u>	ral Cavity a	nd Pharynx		
				Male	16.27	13	80
Female	8.92	1	NC*	Female	8.01	7	87
				Total	24.27	20	82
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>			
Male	66.35	45	68 ~-				
Female	71.26	63	88	Female	18.30	18	98
Total	137.61	108	78 #-				
Esophagus			<u>P</u> :	ancreas			
Male	8.40	6	71	Male	9.04	4	NC*
Female	3.53	6	170	Female	11.01	7	64
Total	11.93	12	101	Total	20.05	11	55 #-
Hodgkin's Dis	ease		<u>P</u> 1	<u>rostate</u>			
Male	3.24	3	NC*	Male	147.85	196	133 ^+
Female	2.79	4	NC*				
Total	6.02	7	116				
Kidney and Re	enal Pelvis		<u>S1</u>	tomach_			
Male	14.08	10	71	Male	11.00	5	45
Female	9.26	7	76	Female	7.90	5	63
Total	23.35	17	73	Total	18.89	10	53 #-
<u>Larynx</u>			$\underline{\mathbf{T}}$	<u>estis</u>			
Male	8.98	3	NC*	Male	4.32	11	255 #+
Female	2.60	3	NC*				
Total	11.58	6	52				
<u>Leukemia</u>			<u>T</u>	<u>hyroid</u>			
Male	9.51	12	126	Male	2.09	4	NC*
Female	7.99	4	NC*	Female	6.07	7	115
Total	17.50	16	91	Total	8.16	11	135
Liver and Intra	<u>ahepatic Bile</u>			<u>teri, Corpu</u>	s and Uterus	<u>NOS</u>	
Male	4.00	3	NC*				
Female	2.05	2	NC*	Female	28.99	32	110
Total	6.04	5	83				
Lung and Bron				ll Sites / Ty			
Male	80.28	35	44 ^-	Male	487.34	471	97
Female	60.04	55	92	Female	492.34	499	101
Total	140.32	90	64 ^-	Total	979.68	970	99

 $\mathbf{Obs} = \mathbf{observed}$ case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

NEW ASHFORD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	\mathbf{Exp}	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urinar	<u>v</u>		<u>M</u>	elanoma of S	<u>Skin</u>				
Male	0.17	1	NC*	Male	0.08	0	NC*		
Female	0.04	0	NC*	Female	0.05	0	NC*		
Total	0.20	1	NC*	Total	0.13	0	NC*		
Brain and Cent	<u>ral Nervous S</u>	<u>ystem</u>	<u>M</u>	<u>ultiple Myel</u>	<u>oma</u>				
Male	0.05	0	NC*	Male	0.03	0	NC*		
Female	0.04	0	NC*	Female	0.02	0	NC*		
Total	0.09	0	NC*	Total	0.05	0	NC*		
Breast			No	on-Hodgkin's	s Lymphoma	<u>a</u> _			
Male	0.01	0	NC*	Male	0.12	0	NC*		
Female	0.64	0	NC*	Female	0.07	0	NC*		
Total	0.65	0	NC*	Total	0.19	0	NC*		
<u>Cervix Uteri</u>			Oral Cavity and Pharynx						
				Male	0.11	0	NC*		
Female	0.04	0	NC*	Female	0.03	0	NC*		
				Total	0.14	0	NC*		
Colon / Rectum	_		<u>O</u>	<u>vary</u>					
Male	0.44	0	NC*						
Female	0.26	0	NC*	Female	0.08	0	NC*		
Total	0.70	0	NC*						
Esophagus			<u>Pa</u>	<u>ancreas</u>					
Male	0.06	0	NC*	Male	0.06	0	NC*		
Female	0.01	0	NC*	Female	0.04	0	NC*		
Total	0.07	0	NC*	Total	0.10	0	NC*		

Hodgkin's Disc	<u>ease</u>		<u>Pr</u>					
Male	0.02	0	NC*	Male	0.97	1	NC*	
Female	0.02	0	NC*					
Total	0.04	0	NC*					
Kidney and Re	nal Pelvis		<u>St</u>	<u>omach</u>				
Male	0.10	0	NC*	Male	0.07	0	NC*	
Female	0.04	0	NC*	Female	0.03	0	NC*	
Total	0.13	0	NC*	Total	0.10	0	NC*	
<u>Larynx</u>			<u>T</u>	<u>estis</u>				
Male	0.06	0	NC*	Male	0.03	0	NC*	
Female	0.01	0	NC*					
Total	0.07	0	NC*					
Leukemia			<u>Tl</u>	<u>nyroid</u>				
Male	0.06	0	NC*	Male	0.02	0	NC*	
Female	0.03	0	NC*	Female	0.03	0	NC*	
Total	0.10	0	NC*	Total	0.05	0	NC*	
Liver and Intra	hepatic Bile I	<u>Ducts</u>	<u>U</u> 1	teri, Corpus	and Uterus, 1	NOS_		
Male	0.03	0	NC*					
Female	0.01	0	NC*	Female	0.12	0	NC*	
Total	0.03	0	NC*					
Lung and Bron	<u>chus</u>		All Sites / Types					
Male	0.54	0	NC*	Male	3.26	2	NC*	
Female	0.25	0	NC*	Female	1.99	0	NC*	
Total	0.78	0	NC*	Total	5.25	2	NC*	

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

NEW BEDFORD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

<u>Exp</u> <u>Obs</u> <u>SIR</u> <u>Exp</u> <u>Obs</u> <u>SIR</u>

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Bladder, Urina	<u>ry</u>		<u>M</u>	Ielanoma of	<u>Skin</u>			
Male	81.93	94	115	Male	39.76	17	43 ^-	
Female	34.38	25	73	Female	35.08	19	54 ~-	
Total	116.32	119	102	Total	74.84	36	48 ^-	
Brain and Cent	<u>tral Nervous</u>	System	$\underline{\mathbf{M}}$	<u> Iultiple Mye</u>	<u>loma</u>			
Male	26.35	14	53 #-	Male	14.63	19	130	
Female	27.54	23	84	Female	15.15	15	99	
Total	53.88	37	69 #-	Total	29.78	34	114	
Breast			<u>N</u>	on-Hodgkin	s Lymphoma	<u>L</u>		
Male	4.26	3	NC*	Male	58.13	51	88	
Female	509.21	471	92	Female	59.46	62	104	
Total	513.47	474	92	Total	117.59	113	96	
Cervix Uteri		Oral Cavity and Pharynx						
				Male	51.76	43	83	
Female	30.66	34	111	Female	26.35	15	57 #-	
				Total	78.11	58	74 #-	
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>				
Male	217.04	205	94					
Female	232.33	231	99	Female	60.79	46	76	
Total	449.36	436	97					
Esophagus			<u>Pa</u>	ancreas				
Male	26.84	26	97	Male	29.42	32	109	
Female	11.54	8	69	Female	36.20	41	113	
Total	38.38	34	89	Total	65.62	73	111	
Hodgkin's Disc	<u>ease</u>		<u>P</u> 1	<u>rostate</u>				
Male	11.74	8	68	Male	488.36	379	78 ^-	
Female	10.24	12	117					
Total	21.98	20	91					
Kidney and Re	enal Pelvis		<u>St</u>	tomach_				
Male	45.65	49	107	Male	35.84	63	176 ^+	
Female	31.00	23	74	Female	25.50	38	149 #+	
Total	76.65	72	94	Total	61.34	101	165 ^+	
<u>Larynx</u>			<u>T</u>	<u>estis</u>				
Male	28.57	40	140 #+	Male	16.44	7	43 #-	
Female	8.57	10	117					
Total	37.13	50	135					
<u>Leukemia</u>			<u>T</u>	<u>hyroid</u>				
Male	31.88	33	104	Male	7.16	8	112	
Female	26.95	38	141	Female	21.22	22	104	
Total	58.83	71	121	Total	28.39	30	106	
Liver and Intra	ahepatic Bile	Ducts	$\underline{\mathbf{U}}$	teri, Corpus	and Uterus,	NOS_		
Male	13.02	11	84					
Female	6.83	12	176	Female	95.56	89	93	
Total	19.85	23	116					

Lung and Bro		All Sites / Types					
Male	260.78	280	107	Male	1601.19	1513	94 #-
Female	201.22	162	81 ~-	Female	1629.14	1526	94 #-
Total	462.01	442	96	Total	3230.33	3039	94 ^-

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

NEW BRAINTREE

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		\mathbf{Exp}	<u>Obs</u>	<u>SIR</u>	
Bladder, Urinary			$\underline{\mathbf{N}}$	<u>lelanoma of S</u>	<u>Skin</u>			
Male	0.55	1	NC*	Male	0.32	1	NC*	
Female	0.15	0	NC*	Female	0.23	0	NC*	
Total	0.71	1	NC*	Total	0.54	1	NC*	
Brain and Central	l Nervous	s System_	Multiple Myeloma					
Male	0.22	0	NC*	Male	0.10	0	NC*	
Female	0.17	0	NC*	Female	0.07	0	NC*	
Total	0.40	0	NC*	Total	0.17	0	NC*	
Breast		Non-Hodgkin's Lymphoma						
Male	0.03	0	NC*	Male	0.46	2	NC*	
Female	2.96	1	NC*	Female	0.30	0	NC*	
Total	2.99	1	NC*	Total	0.76	2	NC*	
<u>Cervix Uteri</u>			<u>O</u>	ral Cavity an	<u>nd Pharynx</u>			
				Male	0.41	0	NC*	
Female	0.22	0	NC*	Female	0.15	0	NC*	
				Total	0.56	0	NC*	
Colon / Rectum		<u>Ovary</u>						
Male	1.47	1	NC*					
Female	1.00	0	NC*	Female	0.37	0	NC*	
Total	2.47	1	NC*					

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Esophagus			<u>Pa</u>	ancreas					
Male	0.20	0	NC*	Male	0.21	0	NC*		
Female	0.05	0	NC*	Female	0.16	1	NC*		
Total	0.25	0	NC*	Total	0.37	1	NC*		
<u>Hodgkin's Di</u>	<u>sease</u>		<u>Pr</u>	<u>rostate</u>					
Male	0.11	0	NC*	Male	3.24	1	NC*		
Female	0.08	0	NC*						
Total	0.19	0	NC*						
Kidney and R	enal Pelvis	enal Pelvis Stomach							
Male	0.35	1	NC*	Male	0.25	0	NC*		
Female	0.17	0	NC*	Female	0.11	1	NC*		
Total	0.52	1	NC*	Total	0.35	1	NC*		
<u>Larynx</u>		<u>Testis</u>							
Male	0.22	0	NC*	Male	0.17	0	NC*		
Female	0.05	0	NC*						
Total	0.27	0	NC*						
<u>Leukemia</u>			<u>Tł</u>	<u>nyroid</u>					
Male	0.25	2	NC*	Male	0.07	0	NC*		
Female	0.15	0	NC*	Female	0.16	0	NC*		
Total	0.40	2	NC*	Total	0.23	0	NC*		
Liver and Int	rahepatic Bile I	<u>Ducts</u>	<u>U</u> 1	teri, Corpus	and Uterus,	NOS_			
Male	0.10	0	NC*						
Female	0.03	0	NC*	Female	0.55	0	NC*		
Total	0.13	0	NC*						
Lung and Bro	<u>nchus</u>	<u>chus</u> <u>All Sites / Types</u>							
Male	1.87	1	NC*	Male	11.44	10	87		
Female	1.07	0	NC*	Female	8.82	3	NC*		
Total	2.94	1	NC*	Total	20.26	13	64		

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

NEW MARLBOROUGH

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\bar{\bf p}$ <= 0.001 level, as well as at the $\bar{\bf p}$ <= 0.05 and $\bar{\bf p}$ <= 0.01 levels

Cancer Incidence by Sex, 1990 - 1995 Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urinar	<u>v</u>		$\underline{\mathbf{M}}$	<u>lelanoma of S</u>	<u>Skin</u>			
Male	1.19	1	NC*	Male	0.58	1	NC*	
Female	0.35	0	NC*	Female	0.41	0	NC*	
Total	1.55	1	NC*	Total	0.99	1	NC*	
Brain and Cent	ral Nervous S	<u>System</u>	$\underline{\mathbf{M}}$	<u>lultiple Myel</u>	<u>oma</u>			
Male	0.39	0	NC*	Male	0.22	0	NC*	
Female	0.32	0	NC*	Female	0.16	0	NC*	
Total	0.71	0	NC*	Total	0.38	0	NC*	
Breast			N	on-Hodgkin's	s Lymphoma	<u>1</u>		
Male	0.06	0	NC*	Male	0.85	0	NC*	
Female	5.89	3	NC*	Female	0.64	0	NC*	
Total	5.95	3	NC*	Total	1.48	0	NC*	
<u>Cervix Uteri</u>			Oral Cavity and Pharynx					
				Male	0.78	0	NC*	
Female	0.37	1	NC*	Female	0.30	0	NC*	
				Total	1.08	0	NC*	
Colon / Rectum			<u>O</u>	<u>vary</u>				
Male	3.19	3	NC*					
Female	2.32	1	NC*	Female	0.71	1	NC*	
Total	5.51	4	NC*					
Esophagus			<u>Pa</u>	<u>ancreas</u>				
Male	0.41	0	NC*	Male	0.44	0	NC*	
Female	0.12	0	NC*	Female	0.38	0	NC*	
Total	0.52	0	NC*	Total	0.81	0	NC*	
Hodgkin's Dise	<u>ase</u>		<u>P</u> 1	<u>rostate</u>				
Male	0.16	0	NC*	Male	7.31	6	82	
Female	0.12	0	NC*					
Total	0.28	0	NC*					
Kidney and Rer	nal Pelvis		<u>St</u>	omach_				
Male	0.69	1	NC*	Male	0.52	0	NC*	
Female	0.35	0	NC*	Female	0.25	0	NC*	
Total	1.05	1	NC*	Total	0.77	0	NC*	
<u>Larynx</u>			$\underline{\mathbf{T}}$	<u>estis</u>				
Male	0.44	0	NC*	Male	0.21	0	NC*	
Female	0.10	0	NC*					
Total	0.54	0	NC*					
Leukemia			<u>T</u>	<u>hyroid</u>				
Male	0.47	1	NC*	Male	0.10	1	NC*	
Female	0.29	0	NC*	Female	0.25	0	NC*	

Total	0.76	1	NC*	Total	0.36	1	NC*		
Liver and Intrahepatic Bile Ducts			<u>Uteri, Corpus and Uterus, NOS</u>						
Male	0.20	0	NC*						
Female	0.07	0	NC*	Female	1.13	0	NC*		
Total	0.27	0	NC*						
Lung and Brono	<u>chus</u>		All Sites / Types						
Male	3.97	1	NC*	Male	23.79	17	71		
Female	2.33	0	NC*	Female	18.14	6	33 ~-		
Total	6.30	1	NC*	Total	41.94	23	55 ~-		

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} <= 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

NEW SALEM

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	<u>SIR</u>			
Bladder, Urinar	<u>v</u>	Melanoma of Skin								
Male	0.61	0	NC*	Male	0.34	1	NC*			
Female	0.20	1	NC*	Female	0.25	0	NC*			
Total	0.81	1	NC*	Total	0.59	1	NC*			
Brain and Cent	ral Nervous S	<u>vstem</u>	<u>M</u>	ultiple Mye	<u>loma</u>					
Male	0.23	0	NC*	Male	0.11	0	NC*			
Female	0.19	0	NC*	Female	0.09	0	NC*			
Total	0.41	0	NC*	Total	0.20	0	NC*			
Breast			No	on-Hodgkin'	s Lymphoma	<u>1</u>				
Male	0.03	0	NC*	Male	0.47	2	NC*			
Female	3.43	3	NC*	Female	0.37	0	NC*			
Total	3.47	3	NC*	Total	0.84	2	NC*			
Cervix Uteri		Oral Cavity and Pharynx								
				Male	0.47	0	NC*			
Female	0.23	1	NC*	Female	0.17	0	NC*			

^{* =} SIR and statistical significance not calculated when Obs < 5

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

				Total	0.64	0	NC*
Colon / Rectum			<u>O</u>	<u>vary</u>			
Male	1.62	1	NC*				
Female	1.35	1	NC*	Female	0.42	1	NC*
Total	2.96	2	NC*				
Esophagus			<u>Pa</u>	ancreas			
Male	0.23	0	NC*	Male	0.23	0	NC*
Female	0.07	0	NC*	Female	0.21	0	NC*
Total	0.29	0	NC*	Total	0.45	0	NC*
Hodgkin's Dise	ase		<u>P1</u>	<u>rostate</u>			
Male	0.10	0	NC*	Male	3.57	2	NC*
Female	0.08	0	NC*				
Total	0.18	0	NC*				
Kidney and Rei	nal Pelvis		<u>St</u>	<u>omach</u>			
Male	0.38	1	NC*	Male	0.27	0	NC*
Female	0.20	0	NC*	Female	0.15	0	NC*
Total	0.58	1	NC*	Total	0.42	0	NC*
<u>Larynx</u>			<u>Te</u>	<u>estis</u>			
Male	0.25	0	NC*	Male	0.14	0	NC*
Female	0.06	0	NC*				
Total	0.31	0	NC*				
Leukemia			<u>Tl</u>	<u>nyroid</u>			
Male	0.26	0	NC*	Male	0.06	0	NC*
Female	0.17	0	NC*	Female	0.16	0	NC*
Total	0.43	0	NC*	Total	0.23	0	NC*
Liver and Intra	hepatic Bile D	<u>ucts</u>	<u>U</u> 1	<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	0.11	0	NC*				
Female	0.04	1	NC*	Female	0.64	0	NC*
Total	0.15	1	NC*				
Lung and Brond	<u>chus</u>		<u>A</u> l	ll Sites / Typ	<u>oes</u>		
Male	2.09	0	NC*	Male	12.45	7	56
Female	1.27	1	NC*	Female	10.51	9	86
Total	3.36	1	NC*	Total	22.96	16	70

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

NEWBURY

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>	
<u>Bladder, Urina</u> ı	<u>ry</u>		<u>M</u>	<u>lelanoma of</u>	<u>Skin</u>			
Male	4.33	1	NC*	Male	2.33	2	NC*	
Female	1.46	0	NC*	Female	1.80	1	NC*	
Total	5.79	1	NC*	Total	4.13	3	NC*	
Brain and Cent	tral Nervous S	<u>System</u>	<u>M</u>	<u>lultiple Mye</u>	<u>loma</u>			
Male	1.57	4	NC*	Male	0.79	1	NC*	
Female	1.38	3	NC*	Female	0.66	1	NC*	
Total	2.95	7	237	Total	1.45	2	NC*	
Breast			No	<u>on-Hodgkin'</u>	s Lymphoma	<u>1</u>		
Male	0.24	0	NC*	Male	3.32	2	NC*	
Female	25.05	29	116	Female	2.68	2	NC*	
Total	25.28	29	115	Total	6.00	4	NC*	
<u>Cervix Uteri</u>		Oral Cavity and Pharynx						
				Male	3.14	1	NC*	
Female	1.68	3	NC*	Female	1.26	1	NC*	
				Total	4.40	2	NC*	
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>				
Male	11.55	10	87					
Female	9.60	12	125	Female	3.08	4	NC*	
Total	21.15	22	104					
Esophagus			<u>Pa</u>	ancreas				
Male	1.55	2	NC*	Male	1.64	2	NC*	
Female	0.48	0	NC*	Female	1.53	2	NC*	
Total	2.03	2	NC*	Total	3.17	4	NC*	
Hodgkin's Dise	<u>ease</u>		<u>P</u> 1	<u>rostate</u>				
Male	0.71	1	NC*	Male	26.07	15	58 #-	
Female	0.56	3	NC*					
Total	1.27	4	NC*					
Kidney and Re	nal Pelvis		St	<u>omach</u>				
Male	2.67	1	NC*	Male	1.90	2	NC*	
Female	1.45	2	NC*	Female	1.04	0	NC*	
Total	4.13	3	NC*	Total	2.95	2	NC*	
<u>Larynx</u>				<u>estis</u>				
Male	1.70	1	NC*	Male	1.02	1	NC*	

Female	0.43	1	NC*				
Total	2.13	2	NC*				
<u>Leukemia</u>			<u>Tl</u>	<u>nyroid</u>			
Male	1.79	3	NC*	Male	0.45	0	NC*
Female	1.26	2	NC*	Female	1.18	0	NC*
Total	3.05	5	164	Total	1.63	0	NC*
Liver and Intra	ahepatic Bile I	<u>Ducts</u>	<u>U</u> 1	NOS			
Male	0.74	1	NC*				
Female	0.30	1	NC*	Female	4.71	8	170
Total	1.04	2	NC*				
Lung and Bron	<u>ichus</u>		<u>A</u>]	ll Sites / Ty	pes		
Male	14.80	11	74	Male	88.53	73	82
Female	9.44	15	159	Female	76.49	93	122
Total	24.25	26	107	Total	165.02	166	101

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

NEWBURYPORT

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary Melanoma of				elanoma of	<u>Skin</u>		
Male	12.24	11	90	Male	6.49	9	139
Female	5.04	0	NC*	Female	5.78	7	121
Total	17.28	11	64	Total	12.27	16	130
Brain and Cent	tral Nervous S	<u>System</u>	Multiple Myeloma				
Male	4.30	4	NC*	Male	2.22	1	NC*
Female	4.32	6	139	Female	2.23	2	NC*
Total	8.62	10	116	Total	4.45	3	NC*
Breast			<u>No</u>	on-Hodgkin'	s Lymphoma	<u>1</u>	
Male	0.66	0	NC*	Male	9.28	5	54

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	80.54	83	103	Female	8.97	7	78
Total	81.20	83	102	Total	18.25	12	66
Cervix Uteri			<u>O</u> :	ral Cavity a	nd Pharynx		
				Male	8.58	8	93
Female	5.31	8	151	Female	4.09	5	122
				Total	12.67	13	103
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>			
Male	32.43	41	126				
Female	33.67	40	119	Female	9.77	6	61
Total	66.11	81	123				
Esophagus			<u>Pa</u>	<u>ancreas</u>			
Male	4.26	5	117	Male	4.51	2	NC*
Female	1.67	2	NC*	Female	5.25	5	95
Total	5.93	7	118	Total	9.77	7	72
Hodgkin's Disc	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Male	2.00	3	NC*	Male	71.12	76	107
Female	1.75	3	NC*				
Total	3.74	6	160				
Kidney and Re	<u>St</u>	<u>omach</u>					
Male	7.27	5	69	Male	5.41	8	148
Female	4.67	6	128	Female	3.73	3	NC*
Total	11.94	11	92	Total	9.14	11	120
<u>Larynx</u>				<u>estis</u>			
Male	4.60	4	NC*	Male	2.96	2	NC*
Female	1.35	0	NC*				
Total	5.95	4	NC*				
<u>Leukemia</u>				<u>hyroid</u>			
Male	4.93	7	142	Male	1.25	0	NC*
Female	4.08	7	172	Female	3.71	6	162
Total	9.01	14	155	Total	4.96	6	121
Liver and Intra	_			<u>teri, Corpus</u>	and Uterus.	NOS	
Male	2.03	3	NC*				
Female	1.00	0	NC*	Female	14.94	13	87
Total	3.03	3	NC*				
Lung and Bron				ll Sites / Ty			
Male	40.12	46	115	Male	244.04	254	104
Female	30.11	38	126	Female	250.44	274	109
Total	70.23	84	120	Total	494.49	528	107

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

NEWTON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR			
Bladder, Urina	ry		$\underline{\mathbf{M}}$	<u>lelanoma of</u>	<u>Skin</u>					
Male	65.55	80	122	Male	33.43	44	132			
Female	25.89	20	77	Female	29.20	35	120			
Total	91.44	100	109	Total	62.63	79	126			
Brain and Cen	tral Nervous	System	$\underline{\mathbf{M}}$	<u>lultiple Mye</u>	eloma_					
Male	21.88	25	114	Male	11.81	14	119			
Female	22.03	22	100	Female	11.45	17	148			
Total	43.91	47	107	Total	23.26	31	133			
Breast			No	<u>on-Hodgkin</u>	's Lymphoma	<u>ı</u>				
Male	3.48	5	144	Male	48.03	70	146 ~+			
Female	408.63	454	111 #+	Female	45.94	65	141 ~+			
Total	412.11	459	111 #+	Total	93.96	135	144 ^+			
Cervix Uteri		Oral Cavity and Pharynx								
				Male	44.14	36	82			
Female	26.63	21	79	Female	20.77	16	77			
				Total	64.92	52	80			
Colon / Rectun	<u>1</u>		<u>O</u>	<u>vary</u>						
Male	173.63	210	121 ~+							
Female	173.60	192	111	Female	49.51	66	133 #+			
Total	347.22	402	116 ~+							
Esophagus			<u>Pa</u>	ancreas						
Male	22.31	19	85	Male	23.92	23	96			
Female	8.58	9	105	Female	27.06	34	126			
Total	30.89	28	91	Total	50.99	57	112			
Hodgkin's Dis	<u>sease</u>		<u>P</u> 1	<u>rostate</u>						
Male	9.83	23	234 ^+	Male	385.09	534	139 ^+			
Female	8.87	6	68							
Total	18.69	29	155 #+							
Kidney and Ro	enal Pelvis		<u>St</u>	<u>omach</u>						
Male	37.88	52	137 #+	Male	28.84	32	111			

Female	23.90	27	113	Female	19.20	22	115	
Total	61.78	79	128 #+	Total	48.04	54	112	
<u>Larynx</u>			<u>Te</u>	<u>estis</u>				
Male	23.99	15	63	Male	14.26	16	112	
Female	6.81	5	73					
Total	30.80	20	65					
Leukemia	<u>nia</u> <u>Thyroid</u>							
Male	25.67	27	105	Male	6.19	12	194 #+	
Female	20.98	34	162 #+	Female	18.63	25	134	
Total	46.65	61	131 #+	Total	24.82	37	149 #+	
Liver and Intr	ahepatic Bile	Ducts	<u>U1</u>	t <mark>eri, Corpus</mark>	s and Uterus,	NOS		
Male	10.67	8	75					
Female	5.15	6	116	Female	75.77	89	117	
Total	15.82	14	88					
<u>Lung and Bronchus</u>				All Sites / Types				
Male	212.53	134	63 ^-	Male	1293.92	1464	113 ^+	
Female	153.93	138	90	Female	1277.32	1421	111 ^+	
Total	366.46	272	74 ^-	Total	2571.24	2885	112 ^+	

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

NORFOLK

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	$\mathbf{\underline{Exp}}$	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urinar	<u>v</u>	Melanoma of Skin							
Male	5.02	5	100	Male	3.57	9	252 #+		
Female	1.09	4	NC*	Female	1.84	3	NC*		
Total	6.11	9	147	Total	5.41	12	222 #+		
Brain and Central Nervous System			<u>M</u>	ultiple Myel					
Male	2.57	3	NC*	Male	0.94	1	NC*		

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	1.38	1	NC*	Female	0.51	1	NC*
Total	3.95	4	NC*	Total	1.45	2	NC*
Breast			No	on-Hodgkin	's Lymphom	<u>a_</u>	
Male	0.30	0	NC*	Male	5.03	9	179
Female	23.23	13	56 #-	Female	2.25	8	356 ~+
Total	23.53	13	55 #-	Total	7.28	17	234 ~+
Cervix Uteri			<u>O</u> :	ral Cavity a	nd Pharynx		
				Male	4.62	4	NC*
Female	1.87	0	NC*	Female	1.12	0	NC*
				Total	5.75	4	NC*
Colon / Rectum	<u>L</u>		$\overline{\mathbf{O}}$	<u>vary</u>			
Male	13.37	11	82				
Female	6.89	5	73	Female	3.00	4	NC*
Total	20.26	16	79				
Esophagus			<u>Pa</u>	<u>ancreas</u>			
Male	2.02	2	NC*	Male	2.05	3	NC*
Female	0.34	0	NC*	Female	1.13	2	NC*
Total	2.36	2	NC*	Total	3.17	5	158
Hodgkin's Disc	<u>ease</u>		<u>P1</u>	<u>rostate</u>			
Male	1.50	1	NC*	Male	28.27	30	106
Female	0.68	0	NC*				
Total	2.19	1	NC*				
Kidney and Re	nal Pelvis			<u>omach</u>			
Male	3.64	1	NC*	Male	2.29	6	262
Female	1.25	0	NC*	Female	0.76	1	NC*
Total	4.89	1	NC*	Total	3.05	7	230
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	2.30	0	NC*	Male	2.57	1	NC*
Female	0.40	0	NC*				
Total	2.70	0	NC*				
Leukemia				<u>nyroid</u>			
Male	2.55	3	NC*	Male	0.87	2	NC*
Female	1.19	0	NC*	Female	1.37	0	NC*
Total	3.74	3	NC*	Total	2.24	2	NC*
Liver and Intra	<u> </u>			<u>teri, Corpus</u>	and Uterus.	NOS	
Male	0.98	2	NC*				
Female	0.24	0	NC*	Female	4.27	1	NC*
Total	1.22	2	NC*				
Lung and Bron			· · · · · · · · · · · · · · · · · · ·	ll Sites / Ty		4.5	
Male	18.19	13	71	Male	111.37	113	101
Female	7.82	6	77	Female	67.16	54	80
Total	26.01	19	73	Total	178.54	167	94

Exp = expected case count, based on the Massachusetts average age-specific incidence rates for this cancer **Obs** = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

NORTH ADAMS

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urina	<u>v</u>		<u>M</u>	elanoma of	<u>Skin</u>			
Male	12.68	9	71	Male	6.33	8	126	
Female	5.57	5	90	Female	5.75	5	87	
Total	18.25	14	77	Total	12.08	13	108	
Brain and Cent	ral Nervous	<u>System</u>	Multiple Myeloma					
Male	4.23	5	118	Male	2.27	1	NC*	
Female	4.53	4	NC*	Female	2.47	1	NC*	
Total	8.76	9	103	Total	4.74	2	NC*	
Breast			No	on-Hodgkin'	s Lymphoma	<u>1</u>		
Male	0.66	0	NC*	Male	9.27	6	65	
Female	83.22	87	105	Female	9.71	8	82	
Total	83.88	87	104	Total	18.98	14	74	
<u>Cervix Uteri</u>			Oral Cavity and Pharynx					
				Male	8.17	10	122	
Female	5.06	5	99	Female	4.28	3	NC*	
				Total	12.45	13	104	
Colon / Rectum	_		$\overline{\mathbf{O}}$	<u>vary</u>				
Male	33.62	42	125					
Female	37.68	47	125	Female	9.96	17	171	
Total	71.30	89	125 #+					
Esophagus			<u>Pa</u>	ancreas				
Male	4.18	4	NC*	Male	4.58	7	153	
Female	1.87	3	NC*	Female	5.90	6	102	
Total	6.05	7	116	Total	10.48	13	124	
Hodgkin's Dise	<u>ease</u>		<u>P</u> 1	<u>rostate</u>				

Male	1.98	1	NC*	Male	75.26	54	72 #-
Female	1.72	4	NC*				
Total	3.69	5	135				
Kidney and Re	enal Pelvis		St	<u>omach</u>			
Male	7.17	6	84	Male	5.56	6	108
Female	5.08	6	118	Female	4.12	2	NC*
Total	12.25	12	98	Total	9.68	8	83
Larynx			<u>Te</u>	<u>estis</u>			
Male	4.46	1	NC*	Male	2.89	3	NC*
Female	1.39	4	NC*				
Total	5.86	5	85				
Leukemia			<u>Tł</u>	<u> </u>			
Male	5.03	6	119	Male	1.19	1	NC*
Female	4.41	8	181	Female	3.52	1	NC*
Total	9.44	14	148	Total	4.71	2	NC*
Liver and Intr	ahepatic Bile	Ducts	Uteri, Corpus and Uterus, NOS				
Male	2.04	5	246				
Female	1.11	0	NC*	Female	15.62	21	134
Total	3.15	5	159				
Lung and Bron	<u>ichus</u>		<u>A</u> l	ll Sites / Ty	<u>pes</u>		
Male	40.54	63	155 ~+	Male	249.75	250	100
Female	33.11	46	139 #+	Female	266.10	300	113 #+
Total	73.65	109	148 ^+	Total	515.86	550	107

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

NORTH ANDOVER

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

Exp Obs SIR Exp Obs SIR

Bladder, Urinary Melanoma of Skin

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	15.82	13	82	Male	8.65	9	104	
Female	6.18	5	81	Female	7.43	11	148	
Total	22.00	18	82	Total	16.08	20	124	
Brain and Cent		<u>System</u>	<u>M</u>	ultiple Mye				
Male	5.91	5	85	Male	2.88	2	NC*	
Female	5.67	3	NC*	Female	2.76	3	NC*	
Total	11.58	8	69	Total	5.64	5	89	
Breast			No	on-Hodgkin'	s Lymphom	<u>a</u>		
Male	0.86	0	NC*	Male	12.31	7	57	
Female	102.45	104	102	Female	11.25	18	160	
Total	103.31	104	101	Total	23.56	25	106	
Cervix Uteri			<u>O</u> 1	ral Cavity a	nd Pharynx			
				Male	11.54	13	113	
Female	6.91	6	87	Female	5.15	6	117	
				Total	16.69	19	114	
Colon / Rectum	<u>l</u>		<u>O</u>	<u>vary</u>				
Male	41.93	43	103					
Female	41.17	52	126	Female	12.56	17	135	
Total	83.09	95	114					
Esophagus			<u>Pa</u>	ncreas				
Male	5.64	6	106	Male	5.92	5	84	
Female	2.03	2	NC*	Female	6.49	6	92	
Total	7.67	8	104	Total	12.41	11	89	
Hodgkin's Dis	<u>ease</u>		<u>Pr</u>	<u>costate</u>				
Male	2.78	1	NC*	Male	91.92	122	133 ~+	
Female	2.38	2	NC*					
Total	5.16	3	NC*					
Kidney and Re	enal Pelvis		<u>St</u>	<u>omach</u>				
Male	9.68	10	103	Male	7.01	11	157	
Female	5.96	7	117	Female	4.53	3	NC*	
Total	15.64	17	109	Total	11.54	14	121	
<u>Larynx</u>			<u>Te</u>	<u>estis</u>				
Male	6.16	0	NC*	Male	4.04	4	NC*	
Female	1.71	0	NC*					
Total	7.87	0	NC*					
Leukemia			<u>Tł</u>	<u>ıyroid</u>				
Male	6.70	8	119	Male	1.69	3	NC*	
Female	5.30	5	94	Female	4.90	7	143	
Total	12.01	13	108	Total	6.59	10	152	
Liver and Intra	Liver and Intrahepatic Bile Ducts <u>Uteri, Corpus and Uterus, NOS</u>							
Male	2.69	2	NC*					
Female	1.26	0	NC*	Female	19.01	24	126	
Total	3.95	2	NC*					
Lung and Bronchus			All Sites / Types					

Male	52.70	36	68 #-	Male	319.83	318	99
Female	38.28	34	89	Female	316.49	344	109
Total	90.98	70	77 #-	Total	636.32	662	104

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

NORTH ATTLEBOROUGH

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urina	<u>ry</u>		<u>M</u>	elanoma of	<u>Skin</u>				
Male	14.65	16	109	Male	8.57	15	175		
Female	5.44	4	NC*	Female	7.28	6	82		
Total	20.09	20	100	Total	15.85	21	133		
Brain and Cent	tral Nervous S	<u>System</u>	<u>M</u>	<u>ultiple Mye</u>	<u>loma</u>				
Male	6.04	7	116	Male	2.69	2	NC*		
Female	5.48	7	128	Female	2.45	2	NC*		
Total	11.52	14	122	Total	5.13	4	NC*		
Breast			Non-Hodgkin's Lymphoma						
Male	0.81	1	NC*	Male	12.32	8	65		
Female	95.78	110	115	Female	10.29	9	87		
Total	96.59	111	115	Total	22.61	17	75		
Cervix Uteri			<u>O</u> :	ral Cavity aı	nd Pharynx				
				Male	11.18	12	107		
Female	7.10	4	NC*	Female	4.76	1	NC*		
				Total	15.94	13	82		
Colon / Rectum	<u>ı</u>		<u>O</u>	<u>vary</u>					
Male	39.00	42	108						
Female	35.85	40	112	Female	11.98	17	142		
Total	74.84	82	110						
Esophagus			<u>Pa</u>	ancreas					

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Male	5.31	4	NC*	Male	5.61	5	89
Female	1.77	2	NC*	Female	5.69	8	141
Total	7.08	6	85	Total	11.30	13	115
Hodgkin's Dis	<u>ease</u>		<u>Pr</u>	<u>costate</u>			
Male	3.14	7	223	Male	86.11	77	89
Female	2.56	6	235				
Total	5.69	13	228 #+				
Kidney and Ro	enal Pelvis		<u>St</u>	<u>omach</u>			
Male	9.35	4	NC*	Male	6.52	3	NC*
Female	5.47	5	91	Female	3.94	5	127
Total	14.82	9	61	Total	10.46	8	76
<u>Larynx</u>			<u>Te</u>	<u>estis</u>			
Male	5.86	6	102	Male	4.90	4	NC*
Female	1.59	1	NC*				
Total	7.45	7	94				
<u>Leukemia</u>			<u>T</u>	<u>iyroid</u>			
Male	6.60	6	91	Male	1.84	1	NC*
Female	5.00	4	NC*	Female	5.12	4	NC*
Total	11.59	10	86	Total	6.96	5	72
Liver and Intr	<u>ahepatic Bile</u>	<u>Ducts</u>	<u>U1</u>	t <mark>eri, Corpus</mark>	and Uterus	, NOS	
Male	2.58	0	NC*				
Female	1.13	0	NC*	Female	17.58	14	80
Total	3.72	0	NC*				
Lung and Bron	<u>ichus</u>		<u>A</u> l	ll Sites / Ty	<u>pes</u>		
Male	50.01	61	122	Male	305.62	303	99
Female	34.76	33	95	Female	291.93	304	104
Total	84.77	94	111	Total	597.55	607	102

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

NORTH BROOKFIELD

Cancer Incidence by Sex, 1990 - 1995

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		\mathbf{Exp}	<u>Obs</u>	<u>SIR</u>
Bladder, Urinar	<u>'Y</u>		$\underline{\mathbf{M}}$	<u>lelanoma of</u>	<u>Skin</u>		
Male	3.60	7	194	Male	1.84	1	NC*
Female	1.18	2	NC*	Female	1.39	1	NC*
Total	4.78	9	188	Total	3.24	2	NC*
Brain and Cent	ral Nervous S	<u>System</u>	$\underline{\mathbf{M}}$	<u>lultiple Mye</u>	<u>loma</u>		
Male	1.26	4	NC*	Male	0.65	0	NC*
Female	1.08	2	NC*	Female	0.53	0	NC*
Total	2.34	6	257	Total	1.18	0	NC*
Breast				<u>on-Hodgkin'</u>	s Lymphoma	<u>ı</u>	
Male	0.19	0	NC*	Male	2.70	2	NC*
Female	19.23	15	78	Female	2.14	1	NC*
Total	19.42	15	77	Total	4.85	3	NC*
<u>Cervix Uteri</u>			<u>O</u>				
				Male	2.39	0	NC*
Female	1.30	2	NC*	Female	0.97	1	NC*
				Total	3.36	1	NC*
Colon / Rectum	_		<u>O</u>	<u>vary</u>			
Male	9.59	6	63				
Female	7.84	6	76	Female	2.36	1	NC*
Total	17.43	12	69				
Esophagus			<u>Pa</u>	ancreas			
Male	1.21	1	NC*	Male	1.32	0	NC*
Female	0.39	2	NC*	Female	1.24	0	NC*
Total	1.60	3	NC*	Total	2.56	0	NC*
Hodgkin's Dise	ease		<u>P</u> 1	<u>rostate</u>			
Male	0.59	2	NC*	Male	21.63	20	92
Female	0.46	0	NC*				
Total	1.05	2	NC*				
Kidney and Re	nal Pelvis		<u>St</u>	<u>omach</u>			
Male	2.10	1	NC*	Male	1.58	3	NC*
Female	1.14	0	NC*	Female	0.86	0	NC*
Total	3.25	1	NC*	Total	2.43	3	NC*
<u>Larynx</u>			$\underline{\mathbf{T}}$	<u>estis</u>			
Male	1.30	1	NC*	Male	0.87	0	NC*
Female	0.32	0	NC*				
Total	1.63	1	NC*				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	1.47	1	NC*	Male	0.36	0	NC*
Female	1.01	2	NC*	Female	0.92	2	NC*
Total	2.48	3	NC*	Total	1.28	2	NC*

Liver and Intrahepatic Bile Ducts			<u>Uteri, Corpus and Uterus, NOS</u>					
Male	0.59	0	NC*					
Female	0.24	0	NC*	Female	3.59	6	167	
Total	0.84	0	NC*					
Lung and Bron	Lung and Bronchus			All Sites / Types				
Male	11.81	19	161	Male	72.17	70	97	
Female	7.37	3	NC*	Female	59.98	49	82	
Total	19.18	22	115	Total	132.15	119	90	

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

NORTH READING

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urina	<u>ry</u>		<u>M</u>	elanoma of	<u>Skin</u>		
Male	7.85	7	89	Male	4.52	4	NC*
Female	2.71	1	NC*	Female	3.63	6	165
Total	10.56	8	76	Total	8.15	10	123
Brain and Cent	tral Nervous S	<u>System</u>	<u>M</u>	ultiple Mye	<u>loma</u>		
Male	3.10	5	161	Male	1.44	0	NC*
Female	2.72	1	NC*	Female	1.23	1	NC*
Total	5.82	6	103	Total	2.67	1	NC*
Breast			<u>N</u>	on-Hodgkin'	s Lymphom	<u>a_</u>	
Male	0.44	2	NC*	Male	6.36	6	94
Female	49.11	55	112	Female	5.08	2	NC*
Total	49.54	57	115	Total	11.44	8	70
Cervix Uteri			<u>O</u> :	ral Cavity aı	nd Pharynx		
				Male	6.13	4	NC*
Female	3.48	7	201	Female	2.45	3	NC*
				Total	8.59	7	82

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Colon / Rectum			<u>O</u>	<u>vary</u>			
Male	20.92	24	115				
Female	17.59	15	85	Female	6.10	6	98
Total	38.51	39	101				
Esophagus			<u>Pa</u>	ncreas			
Male	2.93	3	NC*	Male	3.05	5	164
Female	0.88	0	NC*	Female	2.81	0	NC*
Total	3.81	3	NC*	Total	5.86	5	85
Hodgkin's Disea	<u>ase</u>		<u>P</u> 1	<u>costate</u>			
Male	1.47	1	NC*	Male	46.99	46	98
Female	1.16	1	NC*				
Total	2.63	2	NC*				
Kidney and Ren	al Pelvis		<u>St</u>	<u>omach</u>			
Male	5.06	8	158	Male	3.48	2	NC*
Female	2.76	4	NC*	Female	1.93	0	NC*
Total	7.82	12	153	Total	5.41	2	NC*
<u>Larynx</u>				<u>estis</u>			
Male	3.27	2	NC*	Male	2.20	2	NC*
Female	0.85	0	NC*				
Total	4.12	2	NC*				
Leukemia			<u>Tl</u>	<u> </u>			
Male	3.40	7	206	Male	0.91	0	NC*
Female	2.42	2	NC*	Female	2.46	2	NC*
Total	5.82	9	155	Total	3.37	2	NC*
Liver and Intral	<u>nepatic Bile</u>	Ducts	<u>U</u> 1	t <mark>eri, Corpus</mark>	and Uterus.	NOS	
Male	1.39	2	NC*				
Female	0.56	0	NC*	Female	9.19	11	120
Total	1.96	2	NC*				
Lung and Bronc	<u>hus</u>		$\underline{\mathbf{A}}$	ll Sites / Ty	pes		
Male	27.44	31	113	Male	164.03	167	102
Female	17.77	27	152 #+	Female	147.24	163	111
Total	45.20	58	128	Total	311.27	330	106

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} \le 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

NORTHAMPTON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urina	<u>ry</u>		$\underline{\mathbf{M}}$	<u>lelanoma of</u>	Skin				
Male	22.12	17	77	Male	11.36	5	44		
Female	9.02	8	89	Female	10.44	6	57		
Total	31.14	25	80	Total	21.80	11	50 #-		
Brain and Cent	<u>tral Nervous</u>	<u>System</u>	$\underline{\mathbf{M}}$	<u>lultiple Mye</u>	<u>eloma</u>				
Male	7.40	5	68	Male	3.98	6	151		
Female	7.74	4	NC*	Female	3.93	4	NC*		
Total	15.14	9	59	Total	7.90	10	127		
Breast			<u>N</u>	<u>on-Hodgkin</u>	<u>'s Lymphoma</u>	<u>1</u>			
Male	1.17	0	NC*	Male	16.45	12	73		
Female	139.29	151	108	Female	16.17	13	80		
Total	140.46	151	108	Total	32.62	25	77		
<u>Cervix Uteri</u>			Oral Cavity and Pharynx						
				Male	14.67	16	109		
Female	9.89	4	NC*	Female	7.07	6	85		
				Total	21.74	22	101		
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>					
Male	58.54	49	84						
Female	61.08	49	80	Female	17.06	26	152		
Total	119.62	98	82 #-						
Esophagus			<u>Pa</u>	<u>ancreas</u>					
Male	7.40	10	135	Male	8.01	6	75		
Female	2.99	2	NC*	Female	9.38	7	75		
Total	10.39	12	115	Total	17.39	13	75		
Hodgkin's Disc	<u>ease</u>		<u>P</u> 1	<u>rostate</u>					
Male	3.51	2	NC*	Male	129.05	73	57 ^-		
Female	3.54	4	NC*						
Total	7.06	6	85						
Kidney and Re	enal Pelvis		<u>St</u>	<u>omach</u>					
Male	12.63	11	87	Male	9.75	6	62		
Female	8.13	7	86	Female	6.84	7	102		
Total	20.75	18	87	Total	16.58	13	78		
<u>Larynx</u>			<u>T</u>	<u>estis</u>					
Male	7.91	8	101	Male	5.37	2	NC*		
Female	2.19	1	NC*						

Total	10.10	9	89				
Leukemia			<u>T</u>	<u>nyroid</u>			
Male	8.63	7	81	Male	2.17	1	NC*
Female	7.53	7	93	Female	7.09	11	155
Total	16.16	14	87	Total	9.27	12	129
Liver and Intra	ahepatic Bile	<u>Ducts</u>	<u>U</u> 1	teri, Corpus	and Uterus	, NOS	
Male	3.57	2	NC*				
Female	1.79	0	NC*	Female	25.07	24	96
Total	5.36	2	NC*				
Lung and Bron	<u>ichus</u>		<u>A</u>]	ll Sites / Ty	<u>pes</u>		
Male	70.76	54	76 #-	Male	435.33	321	74 ^-
Female	51.14	40	78	Female	440.82	421	96
Total	121.90	94	77 #-	Total	876.15	742	85 ^-

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} <= 0.05$ level
- ~ indicates statistical significance at the $p \le 0.01$ level, as well as at the $p \le 0.05$ level

NORTHBOROUGH

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>		
Bladder, Urina	ry		<u>M</u>	elanoma of	<u>Skin</u>				
Male	7.22	7	97	Male	4.30	7	163		
Female	2.52	3	NC*	Female	3.54	5	141		
Total	9.75	10	103	Total	7.84	12	153		
Brain and Cen	tral Nervous S	<u>System</u>	<u>M</u>	ultiple Mye	<u>loma</u>				
Male	3.00	6	200	Male	1.33	0	NC*		
Female	2.65	3	NC*	Female	1.15	1	NC*		
Total	5.66	9	159	Total	2.48	1	NC*		
Breast			Non-Hodgkin's Lymphoma						
Male	0.41	0	NC*	Male	6.05	8	132		
Female	47.29	42	89	Female	4.83	0	NC*		

^{* =} SIR and statistical significance not calculated when Obs < 5

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Total	47.70	42	88	Total	10.88	8	74		
<u>Cervix Uteri</u>			<u>O</u> 1	-	<u>nd Pharynx</u>	_			
				Male	5.78	4	NC*		
Female	3.43	4	NC*	Female	2.33	5	215		
				Total	8.11	9	111		
Colon / Rectum	_			<u>vary</u>					
Male	19.19	10	52 #-						
Female	16.38	20	122	Female	5.92	6	101		
Total	35.56	30	84						
Esophagus			<u>Pa</u>	<u>ancreas</u>					
Male	2.72	1	NC*	Male	2.80	2	NC*		
Female	0.81	2	NC*	Female	2.63	2	NC*		
Total	3.53	3	NC*	Total	5.43	4	NC*		
Hodgkin's Disc	ease_		<u>Prostate</u>						
Male	1.49	1	NC*	Male	41.80	29	69 #-		
Female	1.17	1	NC*						
Total	2.66	2	NC*						
Kidney and Re	nal Pelvis		<u>St</u>	<u>omach</u>					
Male	4.72	7	148	Male	3.23	5	155		
Female	2.63	1	NC*	Female	1.80	1	NC*		
Total	7.36	8	109	Total	5.03	6	119		
<u>Larynx</u>			<u>T</u> 6	<u>estis</u>					
Male	3.03	1	NC*	Male	2.25	0	NC*		
Female	0.81	1	NC*						
Total	3.84	2	NC*						
Leukemia			<u>Tì</u>	<u>ivroid</u>					
Male	3.26	0	NC*	Male	0.90	0	NC*		
Female	2.35	3	NC*	Female	2.45	2	NC*		
Total	5.61	3	NC*	Total	3.35	2	NC*		
Liver and Intra	hepatic Bile	Ducts	<u>U1</u>	teri, Corpus	and Uterus	, NOS			
Male	1.29	2	NC*			.			
Female	0.53	0	NC*	Female	8.79	7	80		
Total	1.82	2	NC*						
Lung and Bron	chus_		Al	ll Sites / Ty	pes				
Male	25.02	21	84	Male	150.86	116	77 ~-		
Female	16.86	11	65	Female	140.68	124	88		
Total	41.88	32	76	Total	291.54	240	82 ~-		

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

NORTHBRIDGE

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	SIR		
Bladder, Urina	<u>ry</u>		<u>M</u>	elanoma of	<u>Skin</u>				
Male	10.01	9	90	Male	5.03	5	99		
Female	4.18	6	144	Female	4.34	6	138		
Total	14.19	15	106	Total	9.37	11	117		
Brain and Cent	tral Nervous S	<u>System</u>	<u>M</u>	<u>ultiple Mye</u>	<u>loma</u>				
Male	3.37	4	NC*	Male	1.79	1	NC*		
Female	3.36	2	NC*	Female	1.81	2	NC*		
Total	6.73	6	89	Total	3.60	3	NC*		
Breast			Non-Hodgkin's Lymphoma						
Male	0.53	1	NC*	Male	7.31	5	68		
Female	61.13	41	67 ~-	Female	7.22	5	69		
Total	61.66	42	68 #-	Total	14.53	10	69		
Cervix Uteri			<u>O</u> 1	<u>ral Cavity aı</u>	nd Pharynx				
				Male	6.52	9	138		
Female	3.86	2	NC*	Female	3.17	1	NC*		
				Total	9.69	10	103		
Colon / Rectum	<u>L</u>		<u>O</u>	<u>vary</u>					
Male	26.42	15	57 #-						
Female	28.36	26	92	Female	7.35	6	82		
Total	54.78	41	75						
Esophagus			<u>Pa</u>	ancreas					
Male	3.31	7	211	Male	3.59	2	NC*		
Female	1.40	2	NC*	Female	4.34	4	NC*		
Total	4.71	9	191	Total	7.93	6	76		
Hodgkin's Disc	ease		<u>P</u> 1	<u>rostate</u>					
Male	1.57	3	NC*	Male	58.10	62	107		
Female	1.33	0	NC*						
Total	2.91	3	NC*						
Kidney and Re	nal Pelvis		<u>St</u>	<u>omach</u>					
Male	5.63	5	89	Male	4.42	2	NC*		
Female	3.67	3	NC*	Female	3.17	2	NC*		

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Total	9.29	8	86	Total	7.59	4	NC*
<u>Larynx</u>			<u>T</u>	<u>Cestis</u>			
Male	3.53	1	NC*	Male	2.26	2	NC*
Female	0.99	0	NC*				
Total	4.53	1	NC*				
Leukemia			<u>T</u>	<u>'hyroid</u>			
Male	4.01	4	NC*	Male	0.94	2	NC*
Female	3.37	0	NC*	Female	2.71	0	NC*
Total	7.38	4	NC*	Total	3.65	2	NC*
Liver and Intrahepatic Bile Ducts				Iteri, Corpu	s and Uteru	is, NOS	
Male	1.60	1	NC*				
Female	0.82	1	NC*	Female	11.22	6	53
Total	2.42	2	NC*				
Lung and Bro	onchus_		<u>A</u>	All Sites / Ty	pes		
Male	31.54	30	95	Male	195.42	187	96
Female	23.18	13	56 #-	Female	196.13	141	72 ^-
Total	54.72	43	79	Total	391.55	328	84 ~-

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

NORTHFIELD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>			
Bladder, Urina	<u>iry</u>	Melanoma of Skin								
Male	2.25	2	NC*	Male	1.16	2	NC*			
Female	0.83	2	NC*	Female	0.93	0	NC*			
Total	3.08	4	NC*	Total	2.10	2	NC*			
Brain and Central Nervous System			<u>M</u>	ultiple Myel	<u>oma</u>					
Male	0.78	0	NC*	Male	0.41	0	NC*			
Female	0.72	0	NC*	Female	0.37	0	NC*			

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Total	1.50	0	NC*	Total	0.78	0	NC*			
Breast			<u>N</u>	on-Hodgkin	's Lymphoma	<u>1</u>				
Male	0.12	0	NC*	Male	1.67	1	NC*			
Female	13.15	14	106	Female	1.47	2	NC*			
Total	13.27	14	106	Total	3.14	3	NC*			
Cervix Uteri	<u>Cervix Uteri</u> <u>Oral Cavity and Pharynx</u>									
				Male	1.56	1	NC*			
Female	0.84	0	NC*	Female	0.67	0	NC*			
				Total	2.23	1	NC*			
Colon / Rectum	<u>1</u>		<u>O</u>	<u>vary</u>						
Male	5.98	6	100							
Female	5.53	8	145	Female	1.59	1	NC*			
Total	11.51	14	122							
Esophagus			<u>Pa</u>	ancreas						
Male	0.78	1	NC*	Male	0.83	3	NC*			
Female	0.27	0	NC*	Female	0.87	2	NC*			
Total	1.06	1	NC*	Total	1.70	5	294			
Hodgkin's Dis	<u>ease</u>		<u>P</u> 1	<u>rostate</u>						
Male	0.34	0	NC*	Male	13.40	13	97			
Female	0.28	0	NC*							
Total	0.63	0	NC*							
Kidney and Re	enal Pelvis		St	<u>omach</u>						
Male	1.34	3	NC*	Male	0.99	0	NC*			
Female	0.78	0	NC*	Female	0.61	0	NC*			
Total	2.11	3	NC*	Total	1.60	0	NC*			
<u>Larynx</u>			<u>T</u>	<u>estis</u>						
Male	0.85	0	NC*	Male	0.49	1	NC*			
Female	0.22	0	NC*							
Total	1.07	0	NC*							
<u>Leukemia</u>			<u>T</u>	<u>hyroid</u>						
Male	0.90	1	NC*	Male	0.22	1	NC*			
Female	0.68	0	NC*	Female	0.59	1	NC*			
Total	1.59	1	NC*	Total	0.81	2	NC*			
Liver and Intra	ahepatic Bile	<u>Ducts</u>	<u>U</u> 1	Uteri, Corpus and Uterus, NOS						
Male	0.37	0	NC*							
Female	0.17	0	NC*	Female	2.46	3	NC*			
Total	0.54	0	NC*							
Lung and Bron	<u>chus</u>		<u>A</u>]	ll Sites / Typ	<u>oes</u>					
Male	7.47	8	107	Male	45.06	47	104			
Female	5.02	4	NC*	Female	41.10	39	95			
Total	12.49	12	96	Total	86.17	86	100			

Obs = observed case count

SIR = standardized incidence ratio [(Obs / Exp) X 100]

- * = SIR and statistical significance not calculated when Obs < 5
- + indicates number of observed cases is statistically significantly higher than the expected number of cases
- indicates number of observed cases is statistically significantly lower than the expected number of cases
- # indicates statistical significance at the $\mathbf{p} \le 0.05$ level
- \sim indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level
- ^ indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

NORTON

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>	
Bladder, Urina	<u>ry</u>		<u>M</u>	<u>lelanoma of</u>	<u>Skin</u>			
Male	7.82	10	128	Male	4.78	10	209 #+	
Female	2.99	2	NC*	Female	4.30	4	NC*	
Total	10.81	12	111	Total	9.08	14	154	
Brain and Cent	ral Nervous S	<u>System</u>	$\underline{\mathbf{M}}$	<u>lultiple Mye</u>	<u>loma</u>			
Male	3.42	2	NC*	Male	1.44	0	NC*	
Female	3.18	3	NC*	Female	1.32	2	NC*	
Total	6.60	5	76	Total	2.77	2	NC*	
Breast			No	<u>on-Hodgkin'</u>	s Lymphoma	<u>1</u>		
Male	0.44	1	NC*	Male	6.84	6	88	
Female	53.83	49	91	Female	5.78	6	104	
Total	54.28	50	92	Total	12.63	12	95	
<u>Cervix Uteri</u>		Oral Cavity and Pharynx						
				Male	6.21	4	NC*	
Female	4.34	8	184	Female	2.66	7	264 #+	
				Total	8.87	11	124	
Colon / Rectum	L		<u>O</u>	<u>vary</u>				
Male	20.78	18	87					
Female	19.71	13	66	Female	6.85	7	102	
Total	40.49	31	77					
Esophagus		<u>Pancreas</u>						
Male	2.89	2	NC*	Male	3.01	3	NC*	
Female	0.96	3	NC*	Female	3.07	7	228	
Total	3.85	5	130	Total	6.09	10	164	
Hodgkin's Dise	ease_		<u>P</u> 1	<u>rostate</u>				
Male	1.84	1	NC*	Male	44.93	30	67 #-	

Female	1.63	1	NC*				
Total	3.47	2	NC*				
Kidney and Re		Stomach_					
Male	5.12	9	176	Male	3.51	6	171
Female	2.99	1	NC*	Female	2.21	0	NC*
Total	8.11	10	123	Total	5.72	6	105
Larynx			<u>T</u>	<u>estis</u>			
Male	3.20	3	NC*	Male	2.90	0	NC*
Female	0.86	0	NC*				
Total	4.06	3	NC*				
Leukemia			<u>T</u>	<u>hyroid</u>			
Male	3.67	3	NC*	Male	1.06	0	NC*
Female	2.94	2	NC*	Female	3.19	3	NC*
Total	6.61	5	76	Total	4.25	3	NC*
Liver and Intra	hepatic Bile l	<u>Ducts</u>	<u>Uteri, Corpus and Uterus, NOS</u>				
Male	1.40	0	NC*				
Female	0.63	0	NC*	Female	9.59	8	83
Total	2.03	0	NC*				
Lung and Bron	All Sites / Types						
Male	26.79	35	131	Male	164.48	153	93
Female	18.36	13	71	Female	163.27	151	92
Total	45.15	48	106	Total	327.75	304	93

SIR = standardized incidence ratio [(Obs / Exp) X 100]

NORWELL

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	<u>SIR</u>		Exp	<u>Obs</u>	<u>SIR</u>
Bladder, Urinary		Melanoma of Skin					
Male	6.29	5	79	Male	3.59	5	139

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

 $[\]sim$ indicates statistical significance at the $\mathbf{p} <= 0.01$ level, as well as at the $\mathbf{p} <= 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	2.44	0	NC*	Female	3.01	4	NC*
Total	8.74	5	57	Total	6.60	9	136
Brain and Cent	ral Nervous S	<u>System</u>	$\underline{\mathbf{M}}$	<u>lultiple Mye</u>	<u>loma</u>		
Male	2.44	3	NC*	Male	1.16	1	NC*
Female	2.29	1	NC*	Female	1.11	0	NC*
Total	4.73	4	NC*	Total	2.27	1	NC*
Breast			No	on-Hodgkin'	s Lymphoma	<u>a</u>	
Male	0.35	0	NC*	Male	4.99	3	NC*
Female	42.65	54	127	Female	4.45	3	NC*
Total	43.00	54	126	Total	9.44	6	64
<u>Cervix Uteri</u>			<u>O</u> :	<u>ral Cavity aı</u>	nd Pharynx		
				Male	4.99	4	NC*
Female	2.75	2	NC*	Female	2.14	1	NC*
				Total	7.14	5	70
Colon / Rectum	_		<u>O</u>	<u>vary</u>			
Male	16.74	16	96				
Female	15.99	16	100	Female	5.21	1	NC*
Total	32.74	32	98				
Esophagus			<u>Pa</u>	ancreas			
Male	2.39	0	NC*	Male	2.44	2	NC*
Female	0.80	0	NC*	Female	2.55	4	NC*
Total	3.19	0	NC*	Total	5.00	6	120
Hodgkin's Dise	<u>ease</u>		<u>P</u> 1	<u>rostate</u>			
Male	1.08	2	NC*	Male	37.16	74	199 ^+
Female	0.87	0	NC*				
Total	1.95	2	NC*				
Kidney and Re	<u>nal Pelvis</u>			<u>omach</u>			
Male	4.09	4	NC*	Male	2.79	0	NC*
Female	2.43	3	NC*	Female	1.75	3	NC*
Total	6.53	7	107	Total	4.54	3	NC*
<u>Larynx</u>			<u>T</u>	<u>estis</u>			
Male	2.67	0	NC*	Male	1.54	1	NC*
Female	0.75	1	NC*				
Total	3.42	1	NC*				
<u>Leukemia</u>			<u>T</u>	<u>hyroid</u>			
Male	2.69	1	NC*	Male	0.70	2	NC*
Female	2.07	2	NC*	Female	1.90	2	NC*
Total	4.76	3	NC*	Total	2.60	4	NC*
Liver and Intra	hepatic Bile l	<u>Ducts</u>	· · · · · · · · · · · · · · · · · · ·	<u>teri, Corpus</u>	and Uterus,	NOS_	
Male	1.12	2	NC*				
Female	0.50	2	NC*	Female	8.09	13	161
Total	1.62	4	NC*				
Lung and Brone				ll Sites / Typ			
Male	22.11	12	54 #-	Male	130.56	143	110

85 of 87

Female	15.86	11	69	Female	128.76	131	102
Total	37.97	23	61 #-	Total	259.32	274	106

Obs = observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

NORWOOD

Cancer Incidence by Sex, 1990 - 1995

Expected and Observed Case Counts, with Standardized Incidence Ratios

	Exp	<u>Obs</u>	SIR		Exp	<u>Obs</u>	SIR	
Bladder, Urina	ry	<u>Melanoma of Skin</u>						
Male	22.70	20	88	Male	11.52	18	156	
Female	10.15	7	69	Female	10.54	15	142	
Total	32.84	27	82	Total	22.07	33	150 #+	
Brain and Cen	tral Nervous	<u>System</u>	<u>M</u>	ultiple Mye	<u>loma</u>			
Male	7.56	14	185 #+	Male	4.08	2	NC*	
Female	8.02	4	NC*	Female	4.45	5	112	
Total	15.58	18	116	Total	8.53	7	82	
Breast			<u>N</u>	on-Hodgkin	s Lymphom	<u>a</u>		
Male	1.20	0	NC*	Male	16.65	14	84	
Female	151.51	170	112	Female	17.53	19	108	
Total	152.71	170	111	Total	34.19	33	97	
Cervix Uteri			<u>O</u> 1	ral Cavity a	nd Pharynx			
				Male	15.13	9	59	
Female	9.32	5	54	Female	7.82	7	90	
				Total	22.95	16	70	
Colon / Rectun	Colon / Rectum Ovary							
Male	60.25	59	98					
Female	68.47	87	127 #+	Female	18.10	16	88	
Total	128.71	146	113					
Esophagus			<u>Pa</u>	ancreas				
Male	7.67	4	NC*	Male	8.32	10	120	

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases

[#] indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels

Female	3.39	4	NC*	Female	10.61	8	75	
Total	11.07	8	72	Total	18.93	18	95	
Hodgkin's Dis	<u>sease</u>		Prostate					
Male	3.44	3	NC*	Male	135.79	197	145 ^+	
Female	3.02	3	NC*					
Total	6.46	6	93					
Kidney and R	enal Pelvis		5	Stomach				
Male	13.10	12	92	Male	9.95	16	161	
Female	9.03	9	100	Female	7.57	12	158	
Total	22.13	21	95	Total	17.52	28	160 #+	
<u>Larynx</u>]	<u> </u>				
Male	8.27	16	193 #+	Male	5.07	5	99	
Female	2.53	3	NC*					
Total	10.80	19	176 #+					
Leukemia]	<u>Chyroid</u>				
Male	8.86	12	135	Male	2.15	3	NC*	
Female	7.81	6	77	Female	6.42	7	109	
Total	16.67	18	108	Total	8.58	10	117	
Liver and Intr	ahepatic Bil	e Ducts	<u> </u>	Uteri, Corpus and Uterus, NOS				
Male	3.70	4	NC*					
Female	1.99	1	NC*	Female	28.24	34	120	
Total	5.69	5	88					
Lung and Bro	<u> </u>	All Sites / Types						
Male	74.05	99	134 ~+	Male	450.90	548	122 ^+	
Female	58.53	51	87	Female	481.41	513	107	
Total	132.58	150	113	Total	932.31	1061	114 ^+	

Obs – observed case count

SIR = standardized incidence ratio [(**Obs** / **Exp**) X 100]

^{* =} SIR and statistical significance not calculated when Obs < 5

⁺ indicates number of observed cases is statistically significantly higher than the expected number of cases

⁻ indicates number of observed cases is statistically significantly lower than the expected number of cases # indicates statistical significance at the $\mathbf{p} <= 0.05$ level

[~] indicates statistical significance at the $\mathbf{p} \le 0.01$ level, as well as at the $\mathbf{p} \le 0.05$ level

[^] indicates statistical significance at the $\mathbf{p} \le 0.001$ level, as well as at the $\mathbf{p} \le 0.05$ and $\mathbf{p} \le 0.01$ levels